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Depression, a common mental health disorder, is associated with higher risk of cardiovascular 
disease (CVD).  Adults with HIV infection are often burdened with depression.  Although both 
depression and HIV infection are risk factors for CVD, previous studies have not explored how 
co-occurring depression and HIV are associated with CVD outcomes or underlying physiology. 
The aim of this dissertation was to (i) measure the risk of incident heart failure (HF) with co-
occurring major depressive disorder (MDD) and HIV infection; (ii) measure biomarkers of 
inflammation, coagulation, monocyte activation, and metabolism with depression and HIV 
infection; and (iii) provide a comprehensive biomarker profile associated with symptoms of 
major depression in HIV+ and HIV- participants.  We analyzed data from the Veterans Aging 
Cohort Study (VACS), a prospective study of HIV+ and HIV- veterans matched on age, sex, 
race/ethnicity, and geographical region.  In a sample of 81,427 participants, we found that those 
with co-occurring HIV infection and MDD had significantly higher risk of incident HF 
compared to HIV- participants without MDD, after adjusting for covariates.  In a subset of 2,099 
participants, we determined that depression was associated with higher concentrations of 
interleukin-6 and soluble CD14 (biomarkers for inflammation and monocyte activation) in HIV- 
participants but not HIV+ participants.  HIV+ participants had higher concentrations of glucose 
and triglycerides and lower concentrations of high-density lipoprotein cholesterol with 
depression.  In a smaller sample with more extensive biomarker data, we found a significant 
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association between depression and lower concentrations of vascular endothelial growth factor in 
HIV+ participants.  Neither biomarker study supported the hypothesis that co-occurring 
depressive symptoms and HIV infection would interact and produce excessively high 
concentrations of these biomarkers.  The findings from this dissertation are significant for public 
health research and practice.  Depression is extremely common and is a risk factor for CVD.  In 
the future, investigators must elucidate specific mechanisms driving CVD risk with depression 
and identify effective therapies for preventing depression-related CVD morbidity and mortality 
in both HIV- and HIV+ adults.  Meanwhile, clinicians must remain vigilant in identifying and 
managing depressive symptoms, especially among those who are at heightened risk for CVD due 
to HIV infection. 
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1.0  INTRODUCTION 
The idea for this dissertation stemmed from three inter-related observations in the literature.  
First, depression is associated with cardiovascular disease (CVD).  Second, HIV infection is also 
associated with CVD.  Third, depression is common among those with HIV infection.  
Individuals with depression and individuals with HIV infection may share unhealthy behaviors 
that put them at higher risk for CVD.  Alternatively, depression and HIV infection may cause 
subclinical changes, such as changes in biomarker concentrations, which could put them at 
higher risk for CVD.  The following sections describe key papers in three areas: (1.1) depression 
and cardiovascular disease; (1.2) HIV infection and cardiovascular disease; and (1.3) depression 
and HIV infection.  These studies are summarized in tables found in Appendix A. 
1.1 DEPRESSION 
Depression is highly prevalent in the United States (4.4 to 20% of the general population) and is 
responsible for a great deal of disability worldwide.1  Symptoms of this disorder include absence 
of pleasure, motivation, or interest in daily life, feelings of guilt, lack of concentration, poor self-
esteem, sleep disturbances, and altered appetite.2  Depressive symptoms range from mild to 
severe and can be transient or chronic.  Clinical depression, which includes major depressive 
disorder (MDD) and dysthymic disorder, is diagnoses by clinicians who conduct formal in-
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person interviews.  Treatment for depression may include pharmacological or behavioral 
therapy. 
Depression is associated with cardiovascular disease events, including acute myocardial 
infarction, heart failure, and stroke.3  Many systemic changes occur in response to chronic stress 
and depression.  Biomarkers used to measure growth factor, inflammation, immune activation, 
endocrine function, and metabolism are altered with depression and thought to be potential 
mediators of its association with CVD.4  In addition to physiological changes, depression 
enhances maladaptive behavioral changes, such as decreased treatment adherence, decreased 
physical activity, and poor dietary habits, which are also risk factors for cardiovascular disease.3 
1.1.1 Pathophysiological mechanisms 
Depression is associated with systemic damage to multiple organ systems.2  Many previous 
investigators have identified depression as a risk factor for cardiovascular disease, metabolic 
disorder, blood coagulation, overactive stress and endocrine response, inflammation, 
neurogenerative changes, and unhealthy behaviors.  Due to the significant impact of depression 
on human life, the World Health Organization declared depression as the leading cause of 
disability.2  The following paragraphs describe common changes seen in a depressed state. 
Cardiovascular disease  The physiological associations between depression and cardiovascular 
disease are multifactorial.  After a series of upstream changes that occur outside the 
cardiovascular system (described in the following paragraphs), the blood vessels may experience 
increased sympathetic tone, increased vascular resistance, increased blood viscosity, increased 
intima-media thickness, and atherosclerosis, which each contribute to increased blood pressure.2  
These changes are well-known risk factors for coronary artery disease, myocardial infarction, 
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stroke, and heart failure.  With depression, the heart also experiences increased heart rate and 
decreased heart rate variability, which are both associated with left ventricle dysfunction and 
heart failure.2, 5    [Note: The review article by Nemeroff & Goldschmidt-Clermont (2012) 
provides a helpful figure that illustrates the mechanisms associated with depression and CVD5]  
The following paragraphs describe upstream mechanisms that lead to changes in the 
cardiovascular system. 
Metabolic disorder  Biochemical mechanisms exist to manage glucose and lipid levels within the 
blood stream.  When glucose and lipids are poorly controlled, these metabolites accumulate and 
increase the risk for plaque development, obesity, insulin resistance, and diabetes.6  These 
conditions, which tend to cluster together and are referred to as metabolic syndrome, increase 
risk for hypertension, coronary heart disease, heart attack, and death.  Depression is associated 
with obesity, insulin resistance, poor glucose regulation, and diabetes.2  The association between 
depression and obesity or diabetes may be bidirectional. 
Blood coagulation  Platelets, which play an essential role in coagulation, are thought to be 
involved in the association between depression and ischemic heart disease due to increased 
platelet activation during a stress response.7  Elevated cortisol levels increase the rate in which 
platelet surfaces adhere to collagen within the endothelial lining of the vascular wall.  This 
process activates the platelet and causes receptors to bind with fibrinogen. The activated platelet 
secretes the contents of its intracellular granules, which enhances aggregation with additional 
platelets.  Clotting increases risk for ischemic events. 
Observational and randomized clinical trials suggest that selective serotonin reuptake 
inhibitors (SSRIs; an antidepressant) reduce platelet activation.7  Platelet activation can be 
quantified by measuring the concentration of two components of platelet granules, beta-
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thromboglobulin and platelet factor 4, which are released into the plasma during platelet 
activation.  In a randomized clinical trial, six weeks of therapy using the SSRI parosetine was 
associated with decreased beta-thromboglobulin and platelet factor 4 levels among depressed 
ischemic heart disease patients compared to comparators who used nortriptyline, which is in the 
antidepressant class of drugs call non-selective tricyclic antidepresseants (TCAs).8  The 
SADHART study looked at another SSRI, sertraline, and found significantly lower levels of 
beta-thromboglobulin in the treatment group compared to the group that received a placebo.9  As 
with any anticoagulant, SSRI use is associated with a risk for excess bleeding.7  Overall risk of 
morbidity or mortality from bleeding should be considered when evaluating the true benefits of 
SSRI for CVD health. 
Overactive endocrinological / stress response  External stress is responsible for stimulating the 
hypothalamus-pituitary-adrenal gland (HPA) axis.2  Specifically, both corticotrophin-releasing 
hormone (CRH) and arginine vasopressin are released in response to stress, which release 
corticotrophin into the peripheral circulatory system and stimulate the release of corticosteroid 
from the adrenal cortex.  Chronic activation of the HPA axis can lead to downstream 
complications such as elevated blood pressure, elevated heart rate, decreased heart rate 
variability, and platelet activation. 
Inflammation  Investigators have observed an association between depression and activation of 
the immune system and documented elevated levels of pro-inflammatory cytokines among 
individuals with depression.2  A 2010 meta-analysis summarized twenty-four studies that 
compared cytokine concentrations between individuals with major depressive disorder and 
controls.1  The two inflammatory cytokines that were significant in the weighted meta-analysis 
were interleukin-6 and TNF-alpha.   
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Unhealthy behaviors  Depression is often associated with unhealthy behaviors including poor 
diet, smoking, and inactivity, which are each associated with metabolic syndrome, CVD, and 
death.6 
1.1.2 Depression and heart failure 
Compared to the literature describing the association between depression and ischemic CVD 
events, few studies describe the association between depression and heart failure (HF) and no 
meta-analyses exist.  This section summarizes nine studies that describe the association between 
depression and heart failure (Table 6-1).  Eight of the nine studies assessed over 500 participants.  
Overall, majority of the participants were elderly and female.  Eight of the nine studies included 
participants with a mean age over 57 years, while five of the studies had a mean age over 70 
years.  The one study that made a comparison of depression in a younger group of participants 
(mean age = 38 years) investigated a subclinical measure of heart failure.10  Three of the studies 
included only women, while five of the six remaining studies included slightly more women than 
men.   
The methods for defining depression were variable.  In fact, eight unique definitions were 
used in the nine studies.  All nine studies used self-assessment scales to assess severity of 
depressive symptoms as part of their definition.  “Depression” was defined with four different 
scales and seven different cut-off criteria.  Additionally, two studies included a formal diagnosis 
of clinical depression based on a formal interview of the study participant by a trained healthcare 
professional.  The measures for identifying HF also ranged in methodology.   Methods for 
assessing HF status ranged from adjudicated hospital records by a team of health care 
professionals to self-reported history of HF-related symptoms by participants.  
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The original paper to consider the association between depression and HF was by 
Whooley et al. in 1998.11  The outcome of this study was mortality due to congestive HF based 
on hospital records and death certificates.  The risk for HF mortality was more than three-times 
higher in those who scored high on the Geriatric Depression Scale compared to those who had 
lower scores.  A limitation to this study was that it did not have data regarding CV events over 
the lifecourse.  Therefore, it is not clear whether these HF deaths were preceded by ischemic 
CVD events.  Nonetheless, the findings of this paper sparked the interest of several investigators 
to assess the significance of incident HF with depression. 
In 2001, Abramson et al. published findings from the first large scale study to specifically 
understand the association between depression and incident HF.11    Their study investigated 
incident HF over a mean of 4.5 years in 4,538 older adults with isolated systolic hypertension 
and reported 2.59 times greater risk in individuals with a baseline Center for Epidemiologic 
Study Depression Scale (CES-D) score ≥ 16 compared to those with a score below 16, after 
adjusting for MI.  The findings emphasized that individuals are at risk for HF independently 
from ischemic CVD events.  A subsequent study of elderly individuals found gender differences 
in the association between depression and HF.12  Williams et al. used a cut-point of 21 on the 
CES-D scale and reported that incident HF was significantly higher in women with depression 
compared to non-depressed women (HR = 1.96; 95% CI, 1.11 – 3.26).  The association was not 
significant in men (HR = 0.62; 95% CI, 0.23 – 1.71).  A third study reported a significantly 
higher risk of HF with depression defined using cut-off points using the BDI scale, but the 
analysis was considered exploratory due to too few events.13 
Two studies did not find a significant risk of HF with depression.14, 15  One of these 
studies was conducted in 1,749 participants.14  Individuals with a baseline CES-D score ≥ 16 
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were not at higher risk of HF (p = 0.65).  The second study was conducted in the Netherlands 
and used both the DSM-III Criteria for major depressive disorder (MDD) and the CES-D score 
to identify depression.15  Incident HF was based on self-reported symptoms, medications, or a 
previous diagnosis.  To obtain adequate power, the HF outcome was lumped with arrhythmia, 
which created a “non-ischemic CVD” group.  The association between MDD and non-ischemic 
CVD was not significant in this cohort (RR = 0.96; 95% CI 0.24 – 3.89). 
Two of the studies provided subclinical measures of HF (respiratory gas exchange 
endpoints and left ventricular changes).10, 16  Depression was associated with decreased 
ventilatory efficiency (p = 0.0012), increased left ventricle mass (p = 0.019), and decreased early 
diastolic velocity (p = 0.006).  Ventilatory inefficiency is a sign that the heart is beginning to fail 
at effectively pumping oxygenated blood through the circulation.  Larger left ventricle (LV) 
mass is related to narrowing of the LV chamber, which could precede diastolic HF. 
The final two studies reported associations between depression and biomarkers.13, 17  
Vaccarino et al. assessed the C-reactive protein (CRP) and interleukin-6 (IL-6) concentrations of 
participants categorized into three levels of depression.13  The trend across levels revealed a 
significant increase in CRP and IL-6 with more severe depression (p < 0.0001 and p = 0.0008, 
respectively).  Although significant, these inflammatory biomarkers explained only a small 
proportion of the association between depression and CVD, which indicates the underlying 
mechanism likely involves pathways other than inflammation.  In HF, collagen is deposited in 
the myocardium and fibrosis occurs.16  Kim et al. reported that depression was associated with 
increased procollagen type I (OR = 1.43; 95% CI 1.00 – 2.03), again suggesting that HF may 
advance with depressive symptoms.   
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Since these studies sampled older adults, the findings are not generalizable to a younger 
population.  However, HF tends to develops with age, and majority of HF patients are over 65 
years.18  Thus, it was justifiable for these studies to be directed at older individuals, and the 
findings remain meaningful in that population.  In three of the four studies reporting subclinical 
markers of HF, the mean age of participants was less than 60 years.  Considering subclinical 
disease precedes clinical manifestations, it makes sense for these studies to sample younger 
populations. 
With the large number of elderly participants included in these studies, survivor bias may 
have influenced some of these findings.  Women have a longer life expectancy compared to men.  
Therefore, the study that found significant risk of HF in women but not men may be due to 
artifact from survivor bias.12  In other words, the men with HF may have died before enrolling in 
the study, potentially biasing the findings towards the null. 
Across these studies, methods for measuring exposure and outcome variables were not 
standardized.  The CES-D is feasible to administer in a large cohort and provides information 
about the presence of depressive symptoms, but the findings are not equivalent to a diagnosis of 
clinical depression.11, 12  The outcome definitions for HF diagnosis also ranged in sensitivity and 
specificity, which may have resulted in misclassification.  Despite differences in measurement, 
however, the trends seemed to be similar across the cohorts. 
Depression was not reevaluated over time.  All of the studies in this review measured 
depression at one point in time, but depressive symptoms have a tendency to vary over the life-
course.  Previous papers have described the difference between a single transient episode of 
depressive symptoms and recurrent depressive symptoms.19, 20  The findings revealed that a 
history of recurrent depressive events, but not a history with a single depressive event, were 
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associated with plaque in the carotid artery and coronary artery calcification.19  Addressing 
frequency or duration of depressive episodes could influence the findings of studies within this 
literature review. 
1.2 HIV INFECTION 
According to the Centers for Disease Control and Prevention, over 1.1 million adults are living 
with HIV infection in the United States.21  Adults with HIV infection (HIV+) are now aging 
successfully due to effective clinical management and antiretroviral therapy (ART).22, 23  The risk 
of chronic disease, however, is greater among HIV+ adults compared to individuals without HIV 
(HIV-).24  Heart failure (HF) is a chronic cardiovascular disease that poses a 20% lifetime risk in 
Americans over age 40, and the risk is substantially higher in HIV+ adults.25-27   
HIV infection is independently associated with CVD.  This association has been 
repeatedly reported for CVD events, such as acute myocardial infarction (AMI), heart failure, 
and stroke.25, 28, 29  Subclinical CVD measures also tend to indicate a greater burden of early 
cardiovascular disease in HIV-infected persons compared to healthy comparators.  For example, 
studies show thicker intima-media thickness (IMT), greater coronary artery calcification (CAC), 
faster pulse-wave velocity (PWV), and endothelial dysfunction with HIV infection.30  Adiposity 
stores are also abnormal with HIV.  Potential mechanisms for the elevated risk of cardiovascular 
disease include direct damage to the arterial wall from the HIV viral particles, arterial damage 
due to chronic inflammation, absence of repair due to loss of CD4+ cells, or secondary effects 
due to highly active antiretroviral therapy (HAART)-induced metabolic syndrome.31 
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1.2.1 Pathophysiological mechanisms  
Antiretroviral therapy-related metabolic disorder  Evidence exists that the protease inhibitor 
class of antiretroviral therapy drugs is associated with cardiovascular disease that results from 
lipid dysfunction.26  However, a recent study found that this association is not significant across 
the whole class of protease inhibitors.  Monforte et al. determined that the protease inhibitor 
atazanavir was not significantly associated with cardiovascular or cerebrovascular disease 
events.32 
HIV exposure to vasculature  Early in the HIV epidemic, before effective therapy existed to 
suppress the viral load and slow the progression to AIDS, clinicians were noticing increased 
rates of myocarditis and opportunistic infections, which quickly resulted in heart failure and 
death.26, 33-35 
Chronic inflammation and inflammaging  HIV is associated with ongoing inflammation.  
Monocytes and macrophages remain activated and produce high levels of CRP, TNF-alpha, IL-6, 
and soluble CD14. [32]  Chronic inflammation is damaging to the vascular walls and leads to 
endothelial dysfunction, which is associated with cardiovascular disease events. 
Blood coagulation  The HIV infection response is also associated with clotting disorders. [32]  
As described in the section above, activated platelets produce signals that increase aggregation 
with other platelets and lead to ischemic events. 
1.2.2 HIV infection and heart failure  
Studies published during the pre-HAART era (prior to 1996) described heart disease that 
developed in AIDS patients.  With AIDS, these patients developed secondary infections and 
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myocarditis, which led to HF.  Today, the manifestations of CVD have shifted to complications 
with aging and chronic HF, as previously noted.  Seven papers comparing HIV-infected and -
uninfected persons in the post-HAART era were included in this review (Table 6-2). 
Only two of the seven papers specifically described heart failure incidence as their 
primary outcome.  The remaining five papers described measures of left ventricle (LV) 
dysfunction using echocardiogram.  While LV dysfunction often precedes heart failure, this 
subclinical measure is not equivalent to a clinical diagnosis of heart failure.36 
The two studies that reported HF diagnoses were considerably larger than the five 
imaging studies.  The imaging studies ranged in size from 46 to 242 participants, while the HF 
studies each included more than 8,000 participants.  With mean participant ages ranging from 34 
to 48 years, the participants were notably younger compared to the articles describing depression 
and heart failure.  One of the studies included only men, while the remaining studies included 
more than 60% men.   
Butt et al. published the first paper to identify a significantly higher risk of HF 
hospitalizations of HIV+ persons compared to HIV- persons in a large cohort study (HR = 1.81; 
95% CI, 1.39 – 2.36).37  This study used ICD-9-CM HF codes from medical records of 
participants enrolled in two large cohort studies: Veterans Aging Cohort Study Virtual Cohort 
(VACS-VC) and the 1999 Large Health Study of Veteran Enrollees (LHS).  A secondary 
analysis revealed a significant association between HIV and HF when the baseline HIV-1 RNA 
concentrations were ≥ 500 copies/mL but not when the viral particles were adequately controlled 
and below 500 copies/mL. 
The other study that compared incident HF in HIV positive and negative individuals 
further stratified the participants by race.38  Using the United States National Hospital Discharge 
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Surveys, Oramasasionwu et al. supported the trend found in the VACS-VC/LHS cohorts.  The 
proportion of HF hospitalizations was higher in those with HIV/AIDS compared to those without 
HIV in both African Americans and whites.  Additionally, the proportion of HF hospitalizations 
in HIV-infected African Americans was significantly higher compared to HIV-infected whites. 
There was a common trend in the five studies that described subclinical measures of the 
heart using echocardiogram images.  HIV-infected persons had significantly poorer measures of 
structure and function compared to those negative for HIV.  Notable findings included: increased 
LV diameter, increased LV mass, decreased wall strain, and decreased LV ejection fraction in 
the HIV-infected participants.39-42  To further differentiate whether alterations to the LV were 
entirely explained by high blood pressure, Grandi et al. stratified participants into four groups: 
HIV-infected hypertensives; HIV-infected normotenstives; HIV-uninfected hypertensives; and 
HIV-uninfected normotensives.  In addition to noting greater LV mass in HIV-infected persons, 
they also found that HIV-infected normotenstives had significantly greater LV mass compared to 
HIV-uninfected normotensives.  They concluded that HIV itself must contribute to the 
commonly observed preclinical changes to the heart. 
1.3 DEPRESSION AND HIV INFECTION 
Depression is common in the US with the general population facing an estimated 6.6% 12-month 
risk of developing major depressive disorder (MDD).43  Depression is one of the most common 
comorbidities of HIV.44  Estimates for 12-month MDD prevalence among HIV+ adults range 
from 5% to 10%.45  A meta-analysis reported that the frequency of MDD diagnoses among HIV+ 
participants was nearly two times higher than the frequency among HIV- participants.46  Like 
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HIV infection, MDD may also increase the risk for HF.11, 12, 47, 48  The estimates of depression 
among those with HIV infection vary widely. 
1.4 UNANSWERED QUESTIONS 
In the literature reviewed above, the risk of incident HF was significantly higher in those defined 
as having depression in three of the five studies reporting this association.  This association was 
supported by four studies that described biomarkers and subclinical measures of HF.  Both 
studies that investigated the association of incident HF in HIV-infected individuals, reported an 
increased risk of HF with infection.  The remaining five studies reported that HIV is positively 
associated with both left ventricle mass and left ventricular dysfunction, which are precursors to 
heart failure. 
The underlying processes that link these conditions are not completely understood.  
Investigators have proposed numerous hypotheses for the pathophysiological mechanisms 
linking HIV to HF and depression to HF.  Interestingly, some of the hypotheses overlap.3, 49   
Two hypotheses that have been suggested as possible mechanisms for both depression 
and HIV are systemic inflammation and autonomic nervous system dysfunction.3, 49  During 
systemic inflammation, pro-inflammatory cytokines are elevated.  The downstream effects of 
this include endothelial dysfunction and impairment of contractile strength of heart muscle cells.  
Dysfunction of the autonomic nervous system increases heart rate, induces vasoconstriction, and 
increases blood pressure.  Each of these conditions make the heart work harder, which could lead 
to HF.  Systemic inflammation and the autonomic nervous system are two candidates for further 
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research in better understanding the physiological mechanisms underlying depression, HIV, and 
HF.   
Although HIV and depression share several physiological pathways that increase the risk 
of cardiovascular disease, current literature lacks observational studies aiming to determine 
whether or not these conditions interact to produce excessive cardiovascular disease.  This 
dissertation will investigate cardiovascular disease outcomes and biomarker concentrations to 
further understand whether HIV and depression interact during the development of 




2.0  VETERANS AGING COHORT STUDY 
2.1 VACS 
The Veterans Aging Cohort Study (VACS) is a large prospective cohort developed to explore the 
association between HIV, HIV treatment, comorbid conditions, and disease outcomes.50  
Investigators developed an algorithm to identify HIV positive patients using electronic medical 
records at the Veterans Administration (VA).  The algorithm identified 47,805 HIV+ Veterans 
within 4.1 million records from the VA system between 1998 and 2004 (Figure 2-1).  The 
Immunology Case Registry, which documents HIV patients in the VA, was used as the gold 
standard for calculating the positive predictive value (88%).  Each HIV+ Veterans identified by 
the algorithm was matched to two HIV negative comparators who were similar in age, sex, 
race/ethnicity, geographical location, and year identified.  The Virtual Cohort dataset includes 
administrative and clinical data, diagnostic and procedure code data, healthcare utilization data, 
and outpatient pharmacy data.  Since the VA is the largest provider for HIV patients in the 
United States, epidemiological findings within the cohort will have significant implications to 
managing healthcare procedures and addressing healthcare costs. 
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 Figure 2-1 Veterans Aging Cohort Study (VACS) participants and data 
2.2 VETERANS AND DEPRESSION 
Depression is common in the VA health care system.  According to a fact sheet provided by the 
National Alliance on Mental Illness, 14% of veterans entering the VA from 2000 – 2007 had a 
diagnosis of depression in their VA medical record.51  Similarly, the RAND Corporation 
surveyed a sample of veterans from Operations Enduring Freedom and Iraqi Freedom in 
Afghanistan and Iraq (N = 1,965) using the Patient Health Questionnaire-8 (PHQ-8) and found 
that 14% had symptoms of major depression.52 
The current VA website for depression refers veterans to their primary care physician for 
an initial evaluation of depressive symptoms and a prescription for antidepressant medication.53  
Mental health professionals (psychiatrists, psychologists, social workers, licensed professional 
counselors, and psychiatric nurses) are recommended if the pharmacological treatments do not 
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relieve symptoms.  The VA provides two evidence-based, non-pharmacological options for 
depression: Cognitive Behavioral Therapy and Acceptance and Commitment Therapy.  
According to the RAND report, just over half of the veterans meeting criteria for post-traumatic 
stress disorder and depression sought professional treatment for their symptoms in the previous 
year, which was similar to the rate for seeking treatment in civilians.52 
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BACKGROUND:  Both HIV and depression are associated with increased heart failure (HF) 
risk.  Depression, a common comorbidity, may further increase the risk of HF among HIV+ 
adults.  We assessed the association of HIV and depression with incident HF risk. 
METHODS AND RESULTS:  Veterans Aging Cohort Study (VACS) participants free from 
cardiovascular disease at baseline (N = 81,427; 26,908 HIV+, 54,519 HIV-) were categorized 
into four groups: HIV- without major depressive disorder (MDD) [reference]; HIV- with MDD; 
HIV+ without MDD; and HIV+ with MDD.  ICD-9 codes from medical records were used to 
determine MDD and the primary outcome, HF.  After 5.8 follow-up years, HF rates per 1000 
person-years were highest among HIV+ participants with MDD (9.32; 95% CI, 8.20-10.6).  In 
Cox proportional hazards models, HIV+ participants with MDD had significantly higher risk of 
HF [adjusted hazard ratio (aHR) = 1.68; 95% CI, 1.45-1.95] compared to HIV- participants 
without MDD.  MDD was associated with HF in separate fully adjusted models for HIV- and 
HIV+ participants (aHR = 1.21; 1.06-1.37 and 1.29; 1.11-1.51, respectively).  Among those with 
MDD, baseline antidepressant use was associated with lower risk of incident HF events (aHR = 
0.76; 0.58-0.99). 
CONCLUSIONS:  Our study is the first to suggest MDD is an independent risk factor for HF in 
HIV+ adults.  These results reinforce the importance of identifying and managing MDD among 
HIV+ patients.  Future studies must clarify mechanisms linking HIV, MDD, antidepressants, and 




Antiretroviral therapy (ART) and effective clinical management have resulted in improved life 
expectancy for adults with HIV infection (HIV+).22, 23  Yet, the risk for cardiovascular disease 
(CVD) is higher for HIV+ adults compared to those without HIV (HIV-).24  The risk of heart 
failure (HF), for example, is significantly higher in HIV+ adults compared to HIV- adults who 
are similar in age, gender, and race/ethnicity (adjusted HR = 1.81; 95% CI, 1.39 – 2.36, in a 
cohort of veterans).25, 26, 54 
Poor mental health is an additional concern for HIV+ adults.  Depression is common in 
the US with the general population facing an estimated 6.6% 12-month risk of developing major 
depressive disorder (MDD).43  Estimates for 12-month MDD prevalence among HIV+ adults 
range from 5% to 10%.45  A meta-analysis reported that the frequency of MDD diagnoses among 
HIV+ participants was nearly two times higher than the frequency among HIV- participants.46  
Like HIV infection, MDD may also increase the risk for HF.11, 12, 47, 48   
Possible mechanisms for the association between HIV and HF include chronic 
inflammation and platelet activation.26  Similarly, depression is associated with autonomic 
nervous system dysregulation, inflammation, and platelet activation.7, 55, 56  It stands to reason 
that HIV+ adults with MDD may be at heightened risk for HF compared to the remaining 
population; however, to date, no studies have examined the risk of HF in individuals burdened 
with co-occurring HIV and MDD. 
We investigated the association between HIV, MDD, and incident HF among a subset of 
HIV+ and HIV- veterans from the Veterans Aging Cohort Study (VACS).  We hypothesized that 
HIV+ participants with MDD would have a significantly higher risk of incident HF than 
participants with only one or neither of these conditions after adjusting for cardiovascular risk 
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Details of the prospective, longitudinal Veterans Aging Cohort Study (VACS) have been 
published previously.50  Since 1998, the VACS continually enrolled HIV+ and age-, sex-, 
race/ethnicity-, and geographic region-matched HIV- veterans in the same calendar year from the 
US Department of Veterans Affairs (VA) system.  For this analysis, data from VACS 
participants alive and enrolled as of April 1, 2003 were extracted from the VA national electronic 
medical record system.  The institutional review boards from the University of Pittsburgh, Yale 
University, and West Haven VA Medical Center approved this study. 
Participants were included in this analysis if they were free of clinical CVD at baseline 
(April 1, 2003).  Prevalent CVD at baseline was defined using International Classification of 
Diseases, Ninth Revision (ICD-9) codes for HF, acute myocardial infarction, unstable angina, 
stroke or transient ischemic attack, peripheral vascular disease, or cardiovascular 
revascularization on or before their baseline date.  The final sample included 81,427 Veterans 
(26,908 HIV+, 54,519 HIV-). 
Independent Variables 
We categorized participants into four groups: HIV- without MDD (reference); HIV- with 
MDD; HIV+ without MDD; and HIV+ with MDD.  Participants were considered HIV+ if they 
had at least one inpatient and/or two or more outpatient ICD-9 codes for HIV at baseline.  The 
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algorithm used to identify HIV+ veterans has high sensitivity (90%), specificity (99.9%), and 
positive predictive value (88%).50 
Participants were considered to have MDD if at least one ICD-9 code for MDD (296.2x 
and 296.3x) was ever in their VA medical record prior to the baseline visit.  In a small study that 
compared MDD diagnoses made by general practitioners in primary care settings compared to 
Diagnostic and Statistical Manual of mental disorders, 4th edition (DSM-IV) criteria ranges for 
MDD, specificity was 89% while sensitivity was 79%.57  These findings were supported by a 
larger study that investigated the validity of billing diagnoses for clinical depression in electronic 
medical records.58 
Dependent Variables 
The primary outcome for this report, HF, was determined using VA and Medicare ICD-9 
codes (428.xx, 429.3, 402.11, 402.91, 425.x), a method shown to have a positive predictive value 
of 94.3%.59  The follow-up time for participants began from their first clinical encounter on or 
after 4/1/2003 and continued until a HF event, death, or the last date of follow-up (12/31/2009).  
Figure 3-1 illustrates the timeline of independent and dependent variables. 
Covariates 
Administrative data were used to obtain age, sex, and race/ethnicity.  Outpatient and 
laboratory reports from baseline visits stored in the VA medical record provided data regarding 
hypertension, diabetes mellitus, lipid concentrations, hemoglobin concentrations, renal function, 
atrial fibrillation, atrial flutter, alcohol abuse or dependence, cocaine abuse or dependence, and 
hepatitis C virus (HCV) infection.  Baseline body mass index (BMI; kg/m2) and smoking status 
were acquired from health factor data collected by the VA and recorded in the VA medical 
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record.  Baseline antidepressant and HMG CoA reductase inhibitor (statin) data were obtained 
from VA pharmacy records.50 
Three hypertension categories were used: none (blood pressure <140/90 mmHg and no 
antihypertensive medication use); controlled (blood pressure <140/90 mmHg and 
antihypertensive medication use); and uncontrolled (blood pressure ≥140/90 mmHg).60  Diabetes 
mellitus diagnosis was determined using a combination of glucose levels, anti-diabetes 
medication, and ICD-9 codes; an algorithm previously validated in the VACS.61  Dyslipidemia 
was assessed using levels of low density lipoprotein cholesterol (LDL-c), high density 
lipoprotein cholesterol (HDL-c), and triglycerides measured in mg/dL.  Statin use was 
determined within six months from enrollment.  Anemia was based on hemoglobin 
concentrations (g/dL), and renal function was based on estimated glomerular filtration rate 
(eGFR; mL/min/1.73 m3).  Alcohol abuse or dependence and cocaine abuse or dependence were 
measured based on ICD-9 codes.62  Hepatitis C virus infection was defined by one or more 
inpatient and/or two or more outpatient ICD-9 codes for a positive HCV antibody test result.63  
Body mass index and smoking status (current, past, and never) were included in the VA 
electronic medical health record following prompts to the clinicians during patient visits.  
Obesity was defined as BMI ≥ 30 kg/m2.  The smoking status reported in this health factor 
dataset has shown high agreement with self-reported smoking status on VACS-8 surveys.64   
Antidepressant use was defined as documentation of a filled prescription for selective 
serotonin reuptake inhibitor (SSRI), tricyclic antidepressant (TCA), or other antidepressant use 
from the VA pharmacy records during the baseline period (1998-2003).  Medications were 
classified as “other” if they were in the following classes: tetracyclic antidepressant, monoamine 
oxidase inhibitor, serotonin-norepinephrine reuptake inhibitor, serotonin antagonist and reuptake 
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inhibitor, norepinephrine reuptake inhibitor, norepinephrine-dopamine reuptake inhibitor, and 
miscellaneous (Supplemental Table, Table 3-5).  Generic and brand names for antidepressants 
were used to search outpatient pharmacy records.  
We included HIV-specific variables (CD4+ T-cell (CD4) counts, HIV-1 RNA, and ART 
use) for HIV+ participants from two time periods: baseline and recent.28  Baseline variables were 
obtained during participant visits within 180 days of the baseline enrollment date (4/1/2003).  
Recent variables were obtained during the visit closest to HF, death, or the last follow-up date 
(12/31/2009).  Antiretroviral medications were based on pharmacy data and categorized by drug 
class [i.e., nucleoside reverse-transcriptase inhibitors (NRTI), nonnucleoside reverse-
transcriptase inhibitors (NNRTI), or protease inhibitors (PI)].  Additionally, four types of ART 
regimens were defined: NRTI with PI; NRTI with NNRTI; other regimen; and no ART use 
(reference).  A previous study reported that 96% of HIV+ veterans obtain their ART medications 
through the VA system.50 
Statistical analysis 
Baseline descriptive statistics were calculated for each HIV/MDD group.  T-tests (or non-
parametric counterpart) and chi-square tests were used to determine significant differences 
between the groups as appropriate.  Incident HF diagnosis rates per 1000 person-years were 
calculated for each HIV/MDD group.  Cox proportional hazards regression was used to model 
the association between HIV/MDD group and incident HF, adjusting for age, sex, race/ethnicity, 
BMI, hypertension, diabetes mellitus, LDL-c, HDL-c, triglycerides, statin use, hemoglobin, renal 
function, atrial fibrillation, atrial flutter, smoking status, alcohol abuse or dependence, cocaine 
abuse or dependence, and HCV infection.  A Kaplan-Meier curve was created to display time to 
incident HF by the four HIV/MDD groups.  Among those with MDD, HF incidence rates per 
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1000 person-years and adjusted hazard ratios were calculated by HIV status and antidepressant 
use.  In a second analysis, we used Cox regression to model the association of MDD and incident 
HF among the HIV+ participants.  This analysis included additional adjustments for baseline and 
recent CD4 counts, HIV-1 RNA, and ART use.  We included only participants with a diagnosis 
of MDD in our third analysis which explored the association between antidepressant use and 
incident HF among HIV+ and HIV- participants. 
3.4 RESULTS 
Within this cohort of 81,427 veterans, MDD prevalence was 17.0% overall and not significantly 
different between HIV+ and HIV- participants (18.8% vs. 16.1%, respectively).  The four 
HIV/MDD groups made up the following proportions of the total sample: HIV- without MDD, 
56.2%; HIV- with MDD, 10.8%; HIV+ without MDD, 26.8%; and HIV+ with MDD, 6.2%. 
Baseline characteristics differed between the four HIV/MDD groups (Table 3-1).  
Regardless of MDD diagnosis, HIV+ participants were more likely than HIV- participants to 
have low HDL-c, high triglycerides, HCV infection, renal disease, anemia, and cocaine abuse or 
dependence and to be current smokers.  However, HIV+ participants were less likely to have 
hypertension, diabetes, and high LDL-c and to be obese.  Regardless of HIV status, participants 
with MDD were more likely than participants without MDD to have diabetes, high triglycerides, 
HCV infection, cocaine abuse or dependence, and alcohol abuse or dependence; to be current 
smokers; and to use antidepressant medications (all with p < 0.05).   
During a median of 5.8 (IQR, 3.3 – 6.6) years of follow-up, there were 2666 incident HF 
events.  The HF rate per 1000 person-years was significantly higher among HIV+ participants 
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with co-occurring MDD compared to rates in the other three groups, i.e. HIV- without MDD, 
HIV- with MDD, and HIV+ without MDD (Table 3-2).   
After adjusting for traditional CVD risk factors, HIV- participants with MDD, HIV+ 
participants without MDD, and HIV+ participants with MDD had higher risk of incident HF than 
HIV- participants without MDD (Table 3-3).  Age, hypertension, diabetes, low hemoglobin, low 
eGFR, atrial fibrillation, current smoking, cocaine abuse or dependence and HCV infection were 
independently associated with increased risk of incident HF.  Hispanic race/ethnicity was 
associated with a lower risk of incident HF.  When this model was additionally adjusted for 
SSRI, TCA, and other antidepressant use, the risk of HF remained elevated among HIV- 
participants with MDD (adjusted HF (aHR) = 1.17; 95% CI, 1.02 – 1.34), HIV+ participants 
without MDD (1.28; 1.16 – 1.41), and HIV+ participants with MDD (1.64; 1.41 – 1.92) 
compared to the referent group.  Participants with co-occurring HIV infection and MDD 
diagnosis had the poorest survival free of HF of all four groups (Figure 3-2).  In an exploratory 
analysis, we found that the multiplicative interaction between HIV and MDD was not significant 
(p = 0.32). 
We further explored incident HF risk in HIV- and HIV+ participants separately.  MDD 
was associated with increased risk of HF in both groups (aHR = 1.21; 95% CI, 1.06 – 1.37 and 
1.29; 1.11 – 1.51, respectively).  Among HIV+ participants, MDD remained a significant risk 
factor for HF after further adjusting for baseline CD4 count, baseline HIV-1 RNA concentration, 
and ART regimen documented at the baseline visit (aHR = 1.30, 95% CI, 1.11 – 1.51).  We 
found similar results when the model included baseline PI, NRTI, and NRTI use; recent CD4 
count, HIV-1 RNA concentration and ART regimen; or recent PI, NRTI, and NRTI use. 
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The majority of participants with MDD had at least one antidepressant prescription 
during the baseline period (90.2%).  Among all participants in the sample with MDD, baseline 
antidepressant use was associated with fewer incident HF events, adjusting for HIV and 
cardiovascular disease risk factors (aHR = 0.76; 95% CI, 0.58 – 0.99).  In a model that stratified 
the MDD participants by both HIV status and antidepressant use, the rates of incident HF were 
highest among HIV+ participants who did not use antidepressants (Table 3-4). 
3.5 DISCUSSION 
Our findings indicate that both depression and HIV are associated with an increased risk of HF in 
veterans, even after adjusting for traditional CVD risk factors, comorbidities, and substance use.  
Participants with co-occurring HIV and MDD had the highest rates and risk of HF relative to 
those with only one of the conditions or neither condition.  Furthermore, among HIV+ veterans, 
depression was associated with an increased risk of HF after additional adjustment for CD4 cell 
count, HIV-1 RNA levels, and ART use.   
Our findings are consistent with previous studies reporting associations between (a) HIV 
and incident HF and (b) depression and incident HF in HIV- samples.25-27, 48  However, this study 
is the first to simultaneously examine HIV status, MDD diagnosis, and antidepressant use as 
predictors of incident HF in a large national cohort of HIV infected and uninfected people.  In 
addition, our results are the first to suggest that MDD is an independent risk factor for HF in 
HIV+ adults.  
The physiological mechanisms underlying the associations of HIV infection and 
depression with future HF have yet to be elucidated.  With HIV infection, the risk of HF may be 
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explained by vascular damage associated with the virus itself, chronic inflammation, lack of 
vascular repair due to CD4 cell depletion, or dyslipidemia following HIV infection or ART-
induced metabolic syndrome.25, 28, 31, 65, 66  With depression, possible mechanisms include 
alterations to the hypothalamic-pituitary-adrenal axis, dysregulation of the autonomic nervous 
system, chronic inflammation, and platelet activation.67, 68  In addition to these physiological 
changes, both HIV infection and depression are associated with unhealthy behavioral changes, 
such as substance use and decreased physical activity, which are risk factors for HF.3, 69 
In this study, HIV+ participants with co-occurring MDD had the highest risk of HF.  The 
Infectious Diseases Society of America has stressed the importance of recognizing depression in 
HIV+ patients.70  Our findings bolster this recommendation by adding another reason for doing 
so – i.e., depression as a potential risk factor for HF.  In Table 3-4, we report preliminary 
evidence that raises the possibility that antidepressant use may decrease the excess risk for HF in 
HIV+ and HIV- adults.  However, a prospective randomized controlled trial is needed to 
determine whether depression is a causal risk factor for HF and whether depression interventions 
reduce the risk of HF in the HIV infected and uninfected populations.2, 71  
There are limitations of this study that warrant discussion.  First, as our participants were 
predominantly men, the findings might not generalize to women.  Second, HF and depression 
were based on ICD-9 codes.  Therefore, some misclassification may have occurred (e.g., patients 
with true MDD or HF was not indicated in their medical record with an ICD-9 code), however, 
such misclassification would have biased our results to the null.  Moreover, previous studies 
have shown that the ICD-9 codes for HF and MDD are highly correlated with clinical 
outcomes.57, 59  Third, baseline depressive disorder diagnosis was used as a predictor.  Depressive 
symptom severity tends to fluctuate over time, and previous findings suggest that the mean of 
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symptom severity assessed at multiple time points is a stronger predictor of subclinical CVD 
than depressive symptom severity assessed at one time point.20  However, because depressive 
episodes are likely to recur in those with a MDD diagnosis, a baseline measure of MDD 
diagnosis should capture those at risk for chronic exposure to the unhealthy impact of 
depression.72, 73  Lastly, our findings that depression treatment is associated with a reduced risk 
of HF among HIV infected veterans with MDD, while novel and intriguing, should be 
interpreted with caution. As this is an observational study and not a randomized control trial, we 
cannot eliminate confounding due to indication associated with the treatment of depression.  
Moreover, improved HF outcomes may be attributed to more frequent visits with a provider and 
better management of CVD risk factors and other medical conditions in addition to MDD 
treatment.  Additionally, only 10% of participants with an MDD diagnosis did not have a 
prescription for an antidepressant during the baseline period.  The high prevalence of treatment is 
likely a reflection of the fact that MDD in our study was determined by clinical diagnostic codes 
and not by a formal depression screening instrument administered to all participants.  It is likely 
that some participants with unrecognized depression existed in our no MDD group.  This 
possible misclassification, however, would lead us to underestimate the strength of the MDD-HF 
relationship, as veterans with unrecognized depression would be included in our referent group. 
In conclusion, HIV and MDD are each associated with an increased risk of incident HF. 
HIV infected Veterans with MDD had the highest rates of and risk for HF as compared to 
Veterans with either HIV, depression, or neither condition.  These results suggest that MDD is a 
possible independent risk factor for HF among HIV+ patients and thus reinforce the importance 
of screening for and effectively managing depression in this patient population.  Future studies in 
both HIV infected and uninfected adults should aim (a) to clarify the mechanisms underlying the 
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depression-HF association and (b) to determine whether evidence-based depression treatment 
may help to reduce HF morbidity and mortality in these populations. 
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3.6 TABLES AND FIGURES 
Table 3-1  Baseline participant characteristics by HIV status and major depressive disorder 
(MDD) diagnosis (N = 81,427)* 
HIV-uninfected HIV-infected 
No MDD MDD No MDD MDD 
Characteristic (n = 45,728) (n = 8,791) (n = 21,850) (n = 5,058) 
Age, years, mean (SD) 48.8 (9.5) 48.1 (7.4) 48.3 (9.7) 47.4 (7.9) 
Male, % 97.5 95.6 97.7 95.3 
Race / Ethnicity, % 
     White 37.0 41.6 37.0 42.5 
     African American 48.0 46.8 48.5 45.9 
     Hispanic 7.5 9.2 6.9 8.2 
     Other 7.4 2.4 7.7 3.4 
Body Mass Index ≥ 30 kg/m2, % 38.7 38.6 13.7 16.6 
Hypertension, % 
     None 58.3 60.8 67.3 68.6 
     Controlled 9.4 10.1 7.0 7.9 
     Uncontrolled 32.4 29.0 25.7 23.6 
Diabetes mellitus, % 20.0 23.1 13.3 16.1 
Lipids, mg/dL, % 
     LDL cholesterol < 100 31.2 33.5 46.2 46.5 
     LDL cholesterol 100 - 129 33.3 33.4 29.7 29.6 
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HIV-uninfected HIV-infected 
No MDD MDD No MDD MDD 
Characteristic (n = 45,728) (n = 8,791) (n = 21,850) (n = 5,058) 
     LDL cholesterol 130 - 159 23.2 21.1 15.9 15.7 
     LDL cholesterol ≥ 160 12.3 12.0 8.2 8.1 
     HDL cholesterol ≥ 60 15.0 13.4 11.1 10.2 
     HDL cholesterol 40 - 59 47.7 45.5 38.0 37.2 
     HDL cholesterol < 40 37.3 41.1 50.9 52.6 
     Triglycerides ≥ 150 37.4 42.2 46.9 49.1 
Statin use within 6 months of 
enrollment, % 
9.4 11.6 6.4 6.8 
Hemoglobin, g/dL, % 
     ≥ 14 73.1 70.9 55.1 57.1 
     12 - 13.9 22.9 24.9 31.9 32.0 
     10 - 11.9 3.2 3.5 9.5 8.5 
     < 10 0.8 0.8 3.5 2.5 
Renal function, mL/min/1.73 m3, % 
     eGFR ≥ 60 95.3 95.9 93.6 94.6 
     eGFR 30 - 59 4.2 3.7 5.2 4.4 
     eGFR < 30 0.5 0.3 1.2 1.1 
Atrial fibrillation, % 1.0 0.8 0.8 0.7 





No MDD MDD No MDD MDD 
Characteristic (n = 45,728) (n = 8,791) (n = 21,850) (n = 5,058) 
     Never 31.4 22.8 28.4 19.3 
     Past 16.5 13.4 13.7 11.0 
    Current 52.1 63.8 57.8 69.7 
Alcohol abuse or dependence, % 10.5 27.5 10.8 28.1 
Cocaine abuse or dependence, % 5.5 16.3 8.5 23.3 
HCV infection, % 13.9 24.0 32.7 43.2 
Antidepressant use, % 
     SSRI 20.4 73.7 22.8 73.6 
     TCA 11.3 25.3 14.7 29.2 
     Other antidepressants† 20.6 70.4 22.2 68.2 
HIV-specific risk factors 
CD4 cell count, mm3, % 
     ≥ 500 at baseline … … 31.4 34.6 
     200 – 499 at baseline … … 40.0 40.5 
     < 200 at baseline … … 28.6 24.9 
     ≥ 500 at recent visit … … 41.5 41.7 
     200 – 499 at recent visit … … 39.2 38.4 
     < 200 at recent visit … … 19.3 20.0 
HIV-1 RNA, ≥ 500 copies/mL at 
baseline, % 




No MDD MDD No MDD MDD 
Characteristic (n = 45,728) (n = 8,791) (n = 21,850) (n = 5,058) 
HIV-1 RNA, ≥ 500 copies/mL at 
recent visit, % 
… … 24.5 26.4 
ART use, % 
     NRTI at baseline … … 48.3 49.6 
  NNRTI at baseline … … 22.6 22.1 
     PI at baseline … … 25.3 27.1 
     NRTI at recent visit … … 73.7 68.1 
     NNRTI at recent visit … … 
     PI at recent visit … … 38.1 39.8 
Regimen, % 
     NRTI + PI at baseline … … 20.4 21.6 
     NRTI + NNRTI at baseline … … 22.1 21.6 
     Other at baseline … … 6.7 7.2 
     No ART at baseline … … 50.9 49.6 
     NRTI + PI at recent visit … … 32.4 34.1 
     NRTI + NNRTI at recent visit … … 35.9 28.6 
     Other at recent visit … … 8.3 8.6 
     No ART at recent visit … … 23.4 28.8 
Abbreviations:  ART, antiretroviral therapy; BMI, body mass index (calculated as kg/m2); eGFR, 
estimated glomerular filtration rate; HCV, hepatitis C virus; HDL, high-density lipoprotein; HIV, 
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Table 3-1 Continued
human immunodeficiency virus; LDL, low-density lipoprotein; MDD, major depressive 
disorder; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-
transcriptase inhibitor; PI, protease inhibitor; SSRI, selective serotonin reuptake inhibitors; TCA, 
tricyclic antidepressants 
*All characteristics were significantly different between groups (p < 0.05) except atrial flutter (p
= 0.201), recent CD4 cell counts (p = 0.492), baseline HIV-1 RNA concentration (p = 0.104), 
baseline NRTI use (p = 0.093), baseline NNRTI use (p = 0.436), and baseline ART regimens (p 
= 0.080) 
† See Supplemental Table for medications included in each antidepressant medication category 
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Table 3-2  Unadjusted rates of incident heart failure by major depressive disorder (MDD) 
diagnosis and HIV status (N = 81,427) 






Rates of HF per 1000 p-y 
(95% CI) 
HIV -- | No MDD 45,728 1,339 6.04 (5.73 – 6.38) 
HIV -- | MDD 8,791 319 6.87 (6.16 – 7.67) 
HIV + | No MDD 21,850 774 7.56 (7.05 – 8.11) 
HIV + | MDD 5,058 234 9.32 (8.20 – 10.60) 
Abbreviations:  HF, heart failure; HIV, human immunodeficiency virus; MDD, major depressive 
disorder; p-y, person-years 
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Table 3-3  Cox proportional hazard regression models examining the association between 
HIV/MDD group and incident heart failure 
Characteristic HR (95% CI) 
HIV / MDD Group 
     HIV -- | No MDD 1 [Reference] 
     HIV -- | MDD 1.19 (1.05 - 1.35) 
     HIV + | No MDD 1.28 (1.16 - 1.41) 
     HIV + | MDD 1.68 (1.45 - 1.95) 
Age, 10 year intervals 1.78 (1.70 - 1.86) 
Female sex 1.01 (0.77 - 1.33) 
Race / Ethnicity 
     White 1 [Reference] 
     African American 1.05 (0.96 - 1.15) 
     Hispanic 0.77 (0.65 - 0.92) 
     Other 0.92 (0.76 - 1.11) 
Body Mass Index ≥ 30 1.25 (1.14 - 1.36) 
Hypertension 
     None 1 [Reference] 
     Controlled 1.78 (1.58 - 2.01) 
     Uncontrolled 1.94 (1.77 - 2.12) 
Diabetes mellitus 1.75 (1.61 - 1.91) 
Lipids, mg/dL 
     LDL cholesterol < 100 1 [Reference] 
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     LDL cholesterol 100 - 129 0.88 (0.79 - 0.98) 
     LDL cholesterol 130 - 159 0.88 (0.78 - 1.00) 
     LDL cholesterol ≥ 160 0.93 (0.78 - 1.12) 
     HDL cholesterol ≥ 60 1 [Reference] 
     HDL cholesterol 40 - 59 1.04 (0.90 - 1.21) 
     HDL cholesterol < 40 1.04 (0.89 - 1.21) 
     Triglycerides ≥ 150 1.00 (0.91 - 1.10) 
Statin use within 6 months 1.08 (0.97 - 1.21) 
Hemoglobin, g/dL 
     ≥ 14 1 [Reference] 
     12 - 13.9 1.32 (1.20 - 1.45) 
     10 - 11.9 1.84 (1.58 - 2.14) 
     < 10 2.23 (1.75 - 2.85) 
Renal function, mL/min/1.73 m3 
     eGFR ≥ 60 1 [Reference] 
     eGFR 30 - 59 2.01 (1.78 - 2.28) 
     eGFR < 30 5.21 (4.31 - 6.30) 
Atrial fibrillation 2.15 (1.63 - 2.84) 
Atrial flutter 1.59 (0.91 - 2.78) 
Smoking 
     Never 1 [Reference] 
     Past 1.09 (0.96 - 1.23) 
     Current 1.42 (1.29 - 1.57) 
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Table 3-3 Continued
Alcohol abuse or dependence 0.98 (0.86 - 1.12) 
Cocaine abuse or dependence 1.27 (1.09 - 1.48) 
HCV infection 1.30 (1.19 - 1.43) 
Abbreviations:  BMI, body mass index (calculated as kg/m2); eGFR, estimated glomerular 
filtration rate; HCV, hepatitis C virus; HDL, high-density lipoprotein; HIV, human 




Table 3-4  Rates and adjusted hazard ratios of incident heart failure among those with baseline 









HF rates per 1000 










HIV -- No 875 36 8.25 (5.95 – 11.44) 1.21 (0.85 – 1.71) 
HIV + Yes 4582 206 8.97 (7.82 – 10.28) 
0.055§ 
1.39 (1.14 – 1.68) 
0.053|| 
HIV + No 476 28 13.20 (9.11 – 19.11) 2.07 (1.39 – 3.08) 
Abbreviations:  aHR, adjusted hazard ratio; CI, confidence interval; HF, heart failure; HIV, 
human immunodeficiency virus; p-y, person-years 
*All models for HF were adjusted for age, sex, race/ethnicity, body mass index, hypertension,
diabetes mellitus, lipids, statin use, hemoglobin, renal function, atrial fibrillation, atrial flutter, 
smoking, alcohol abuse or dependence, cocaine abuse or dependence, and HCV infection 
† P value for the comparison of HF rates; HIV- participants who did not use antidepressants at 
baseline compared to HIV- antidepressant users 
‡ P value for the comparison of aHRs; HIV- participants who did not use antidepressants at 
baseline compared to HIV- antidepressant users 
§ P value for the comparison of HF rates; HIV+ participants who did not use antidepressants at
baseline compared to HIV+ antidepressant users 
|| P value for the comparison of aHRs; HIV+ participants who did not use antidepressants at 
baseline compared to HIV+ antidepressant users 
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Table 3-5  Supplemental Table.  List of antidepressants included in study by class* 
Class Generic Name Brand Name 
Selective Serotonin Reuptake 
Inhibitors (SSRI) 
Citalopram Celexa 
Escitalopram Lexapro, Cipralex 






Amitriptyline Elavil, Endep, Levate 
Clomipramine Anafranil 
Desipramine Norpramin, Pertofrane 
Dosulepin  Dothiepin, Prothiaden 
Doxepin Adapin, Sinequan 
Imipramine Tofranil 







Maprotiline Deprilept, Ludiomil, Psymion 
Mianserin Bolvidon, Norval, Tolvan 
Mirtazapine Remeron 
Monoamine Oxidase Inhibitors Isocarboxazid Marplan 
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(MAOI) Moclobemide Manerix 
Phenelzine Nardil 
Selegiline L-Deprenyl, Eldepryl, Zelapar, 
Emsam 
Tranylcypromine Parnate 
Pirlindole  Pirazidol 
Serotonin-Norepinephrine 




Venlafaxine Effexor, Effexor XR 
Serotonin Antagonist and 
Reuptake Inhibitor (SARI) 
Etoperidone Axiomin, Etonin 
Lubazodone YM-992, YM-35,995 
Nefazodone  Serzone, Nefadar 
Trazodone  Desyrel, Apo-Trazodone 
Norepinephrine Reuptake 
Inhibitor (NRI) 
Reboxetine Edronax , Vestra  
Viloxazine Vivalan 
Norepinephrine-Dopamine 
Reuptake Inhibitor (NDRI) 
Bupropion Wellbutrin, Wellbutrin SR, 
Wellbutrin XL, Zyban 
Dexmethylphenidate Focalin 
Methylphenidate Ritalin, Concerta 
Miscellaneous Tianeptine Stablon 
Viloxazine  Vivalan 
Tandospirone  Sediel 
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Table 3-5 Continued
Ago melatine Valdoxan 
*Medications were classified as “other” if they were in the following classes: tetracyclic
antidepressant, monoamine oxidase inhibitor, serotonin-norepinephrine reuptake inhibitor, 
serotonin antagonist and reuptake inhibitor, norepinephrine reuptake inhibitor, norepinephrine-
dopamine reuptake inhibitor, and miscellaneous 
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Table 3-5 Continued
 Figure 3-1.  Timeline for independent and dependent variables  
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Figure 3-2.  Kaplan Meier survival analysis by major depressive disorder (MDD) diagnosis and 
HIV status (N = 81,427) 
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4.0  ASSOCIATION BETWEEN DEPRESSION AND BIOMARKERS OF 
INFLAMMATION, ALTERED COAGULATION, MONOCYTE ACTIVATION, AND 
METABOLISM IN VETERANS WITH AND WITHOUT HIV INFECTION 
Jessica R. White, MS; Department of Epidemiology, University of Pittsburgh Graduate School 
of Public Health, Pittsburgh, PA, USA; Chung-Chou H. Chang, PhD; Division of General 
Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, 
Pittsburgh, PA, USA; Department of Biostatistics, University of Pittsburgh Graduate School of 
Public Health, Pittsburgh, PA, USA; Kaku A. So-Armah, PhD; Department of Internal 
Medicine, Yale University, New Haven, CT, USA; Amy C. Justice, MD, MSCE, PhD; Yale 
University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Health Care 
System, West Haven Veterans Administration Medical Center, West Haven, CT, USA; and 
Matthew S. Freiberg, MD, MPH;  Cardiovascular Medicine Division, Vanderbilt University 




BACKGROUND:  Major depressive disorder (MDD) is a risk factor for cardiovascular disease 
in veterans with and without HIV infection.  The mechanism underlying this association is not 
clear.  We hypothesized that markers of inflammation, coagulation, monocyte activation, and 
metabolism would be positively associated with depression in a cohort of veterans with and 
without HIV infection. 
METHODS:  Participants in this study were enrolled in the Veterans Aging Cohort Study 
(VACS).  This large, prospective cohort study included HIV+ and HIV- veterans who were 
matched on age, sex, race/ethnicity, and geographical region.  A subset of these participants, free 
of cardiovascular disease, were enrolled in the Biomarker Substudy and provided blood for 
laboratory analysis.  Interleukin-6 (IL-6), d-dimer, soluble CD14 (sCD14), glucose, and lipids 
were quantified.  Depression was defined using medical record diagnoses for major depressive 
disorder (MDD) and self-reported depressive symptoms.  Standard multiple regression models 
provided information about the association between depression, HIV infection, and biomarker 
concentrations, adjusting for possible confounding variables. 
RESULTS:  In this sample of 2,099 participants, 678 (32.3%) had a diagnosis of MDD at 
baseline and 456 (21.7%) participants reported recent symptoms of major depression (Patient 
Health Questionnaire-9 scores ≥ 10).  In models adjusted for HIV and other significant 
covariates, MDD was associated with glucose concentrations in the highest quartile (OR = 1.39; 
95% CI, 1.09 – 1.77) and increased concentrations of LDL-c (β = 3.94; 95% CI, 0.43, 7.45), 
while PHQ-9 scores ≥ 10 were associated with higher triglyceride concentrations (β = 0.08; 95% 
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CI, 0.01 – 0.14).  In models restricted by HIV status and adjusted for age, sex, and race/ethnicity, 
MDD was associated with increased concentrations of IL-6 and sCD14 in the HIV- participants, 
and associated with increased concentrations of glucose and decreased concentrations of HDL-c 
in the HIV+ participants. 
CONCLUSIONS:  In this sample of veterans, we found significant associations between 
depression and altered concentrations of biomarkers.  The changes observed in the HIV- 
participants were different from the changes observed in the HIV+ participants.  These findings 
suggest that the physiological pathways mediating depression and cardiovascular disease may 
differ with co-occurring HIV infection.  To prevent the risk of cardiovascular disease with 
depression, interventionists should consider the HIV status of their patients. 
4.2 INTRODUCTION 
We recently demonstrated that major depressive disorder (MDD) is a risk factor for both incident 
heart failure and acute myocardial in veterans with and without HIV infection.74, 75  It is not clear 
whether depression and HIV infection share physiological mechanisms that drive the elevated 
risk of cardiovascular disease (CVD). 
Clinical depression and depressive symptoms are associated with systemic effects 
including inflammation, coagulation, monocyte activation, and the metabolic syndrome.1, 76-79 
These pathologies are also seen with HIV infection.80, 81  Since depression is highly prevalent 
with HIV infection, it is important to know how the combination of depression and HIV 
infection affect the body at a physiological level.44   
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The objective of this study was to determine whether depression was associated with 
biomarkers for inflammation, altered coagulation, monocyte activation, and metabolism in a 
cohort of veterans with and without HIV infection.  Our primary hypothesis was that depression 
would be associated with significantly higher concentrations of IL-6, d-dimer, soluble CD14, 
glucose, LDL-c, and triglycerides, and significantly lower concentrations of HDL-c in both HIV- 
and HIV+ veterans.  Second, we hypothesized that co-occurring depression and HIV infection 
would interact and be associated with a biomarker profile worse than what would be expected if 
only one of these two conditions were present. 
4.3 METHODS 
Participants 
The Veterans Aging Cohort Study (VACS) is a large, prospective cohort study that 
continuously enrolled HIV+ veterans from the US Department of Veterans Affairs (VA) system 
beginning on April 1, 2003.50  Participants with HIV infection were matched to two HIV-
uninfected participants by age, sex, race/ethnicity, and geographical region during the same 
calendar year.  The Biomarker Substudy is a subset of VACS participants who provided a blood 
sample for analysis of interleukin-6 (IL-6), d-dimer, soluble CD14 (sCD14), and a metabolic 
panel during a clinical visit between 2005 – 2006.80   
Participants were excluded from this analysis if they had pre-existing clinical CVD or if 
they did not complete all nine items on the Patient Health Questionnaire (PHQ-9).  Clinical CVD 
was defined as documentation of International Classification of Diseases, Ninth Revision (ICD-
9) codes for acute myocardial infarction, heart failure, unstable angina, stroke or transient 
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ischemic attack, peripheral vascular disease, or cardiovascular revascularization in the VA 
medical record.  The final sample included 2,099 veterans (1,365 HIV+, 734 HIV-). 
Independent Variables 
During VACS enrollment, participants were classified as HIV+ if their electronic medical 
record included at least one inpatient diagnosis for HIV diagnosis or at least two outpatient HIV 
diagnoses, using ICD-9 codes.50  HIV status was confirmed with the VA’s Immunology Case 
Registry.  This algorithm for HIV status has high sensitivity (90%), specificity (99.9%), and 
positive predictive value (88%).50 
The Biomarker Substudy provided two measures of depression: clinical depression 
diagnosis and self-reported symptoms of major depression.  Clinical depression was defined 
using electronic medical record data.  Participants were classified as having major depressive 
disorder (MDD) if their medical record included at least one ICD-9 code for MDD (296.2x and 
296.3x) between 1998 and the first clinical visit on or after April 1, 2003.  Depressive symptoms 
were determined with the nine-item Patient Health Questionnaire (PHQ-9), a self-assessment that 
measures depressive symptom severity during the two weeks preceding the questionnaire.82  
Cumulative PHQ-9 scores ranging from 0 (least severe) to 27 (most severe) were used to classify 
depression symptom severity.  A PHQ-9 score of 10 or higher has been established as a cut-off 
point associated with symptoms of major depression in the general population (sensitivity, 74%; 
sensitivity 91%).83  PHQ-9 scores were acquired from participant surveys administered during 
the visit most recent to the blood draw. 
  Dependent Variables 
The biomarkers included in this analysis were selected and measured to answer HIV-
specific research questions developed prior to our depression-specific aims in this analysis.  
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Therefore, we were limited to measuring inflammation, coagulation, monocyte activation, and 
altered metabolism using pre-existing lab results for interleukin-6, d-dimer, soluble CD14, and 
the basic metabolic panel, respectively.  Although we used pre-existing laboratory data, these 
biomarkers were biologically plausible and warranted investigation for understanding depression 
physiology in HIV- and HIV+ adults. 
Participant plasma in sodium citrate and serum were collected during a clinical visit 
between 2005 and 2006.  Biomarkers were analyzed at the University of Vermont’s Laboratory 
for Clinical Biochemistry Research.  Serum concentration (pg/mL) of the inflammatory 
biomarker interleukin-6 (IL-6) was quantified by chemiluminescent sandwich enzyme-linked 
immunosorbent assay (ELISA) using R&D Systems, Inc.  D-dimer, a marker of coagulation, was 
measured in participant plasma using the Stago STA-R Analyzer.  The biomarker for monocyte 
activation, soluble CD14 (sCD14), was measured in serum (ng/mL) with sandwich ELISA on the 
R&D Systems analyzer.  Serum glucose and lipid concentrations were obtained from VA 
laboratory records.  Figure 4-1 illustrates the timeline of independent and dependent variables. 
Covariates 
Administrative records were used to collect data regarding age, sex, and race/ethnicity.  
Outpatient medical, laboratory, and pharmacy records provided data on blood pressure, diabetes 
mellitus, hepatitis C virus (HCV) infection, HMG CoA reductase inhibitor (statin) use within six 
months of enrollment, alcohol abuse, and cocaine use.  The VA collected health factor data 
regarding body mass index (BMI; kg/m2) that was recorded in VA medical records.50  Smoking 





Both the percentage of observed agreement and kappa statistic (κ) were calculated to 
understand the degree of agreement between our two classifications for depression: a diagnosis 
of MDD and a score of greater than or equal to 10 on the PHQ-9.84  
We compared the prevalence of MDD and symptoms of major depression in HIV+ and 
HIV- participants using chi-square analysis.  In a table of baseline characteristics stratified by 
HIV status and depression, continuous and categorical variables were compared using ANOVA 
and chi-square analyses, respectively.   
For each HIV / depression group, we provided means with standard deviations for 
normally distributed biomarkers (sCD14, LDL-c, and HDL-c); and medians with interquartile 
ranges for non-normally distributed biomarkers (IL-6, d-dimer, glucose, and triglyceride).  
Within HIV strata, we compared mean and median biomarker concentrations in those with and 
without depression using two-sample T tests and Wilcoxon two-sample tests, as appropriate.  
Across the four groups, we compared biomarker concentrations using ANOVA.  We also 
provided the proportion of participants with biomarker concentrations in the highest 75th 
percentile for each HIV / depression group.  These values were compared within HIV strata and 
across the four groups using chi-square analyses. 
In standard multiple regression models, we modeled the association between MDD and 
the continuous biomarker concentrations (sCD14, LDL-c, and HDL-c) or log transformed 
biomarker concentrations (IL-6, d-dimer, glucose, and triglycerides).  The multiplicative 
interactions between MDD and HIV infection were tested for significance.  Models were 
adjusted for (1) HIV, age, sex, and race/ethnicity; and (2) HIV, age, sex, race/ethnicity, and 
variables that were significantly different between the four HIV / MDD groups in Table 4-3.  
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Using logistic regression, we determined whether the odds of having biomarker concentrations in 
the highest quartile were associated with MDD, adjusting for the same covariates listed above.  
In a second analysis, we stratified the models between MDD and biomarkers by HIV status.  All 
of these models were repeated using the PHQ-9 criteria for depression.  Significant associations 
were defined as those with p values < 0.05. 
4.4 RESULTS 
The prevalence of baseline MDD in this cohort of 2,099 veterans was 32.3%, while the 
prevalence of having recent symptoms of major depression using a PHQ-9 score of greater than 
or equal to ten was 21.7% (Table 4-1).  The observed agreement between these two 
classifications was 71.6% (κ = 0.29).  Kappa statistics ranging between 0.21 and 0.40 are 
interpreted as having fair agreement.84 
The prevalence of MDD was not significantly different between HIV- and HIV+ 
participants (34.3% and 31.2%, respectively; p = 0.14; Table 4-2).  A significantly higher 
proportion of HIV- participants had symptoms of major depression, i.e., PHQ-9 ≥ 10, (25.6%) 
compared to HIV+ participants (19.6%).  Uninfected participants tended to have a higher 
frequency of PHQ-9 scores between 15 and 19, indicating symptoms of moderate major 
depression, and scores greater than or equal to 20 indicating symptoms of severe major 
depression. 
Race / ethnicity, baseline diastolic blood pressure, and statin use within six months of 
enrollment were not significantly different across the four HIV / MDD groups (Table 4-3).  The 
mean age was highest in the HIV- participants without MDD.  Those with MDD were more 
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likely to be female, current smokers, have HCV infection, and use antidepressants.  The HIV+ 
participants had lower BMIs and systolic blood pressures, were less likely to have diabetes and 
more likely to have HCV infection.  In HIV+ participants, ART use was similar by depression 
status, but those with MDD tended to have higher HIV-1 RNA copies/mL and lower CD4:CD8 
ratios.  Baseline characteristics by HIV status and PHQ-9 score are provided in a Supplemental 
Table (Table 4-10).   
In Tables 4-4 and 4-5, we provided mean concentrations for normally distributed 
biomarkers (sCD14, LDL-c, and HDL-c) and median concentrations for non-normally 
distributed biomarkers (IL-6, d-dimer, glucose, and triglyceride) by HIV / depression group.  
Among HIV- participants, those with MDD had higher concentrations of IL-6 and sCD14 
compared to those without MDD (Table 4-4).  Participants with HIV infection and co-occurring 
MDD had higher concentrations of glucose and triglycerides and lower concentrations of HDL-c 
compared to HIV+ participants without MDD.  Using the PHQ-9 criteria, symptoms of major 
depression were associated with higher concentrations of IL-6 in the HIV- participants and with 
higher concentrations of triglycerides in the HIV+ participants (Table 4-5). 
In standard multiple regression models, which included MDD, HIV infection, age, sex, 
and race/ethnicity, MDD was associated with higher concentrations of d-dimer and glucose 
(Table 4-6).  Logistic regression models produced similar results: MDD was associated with 
concentrations of d-dimer and glucose in the highest quartile.  In these models, HIV infection 
was associated with higher concentrations of IL-6 and triglycerides and lower concentrations of 
d-dimer, glucose, LDL-c, and HDL-c.  In the fully adjusted models, MDD was associated with 
higher concentrations of LDL-c and glucose concentrations in the highest quartile.  HIV 
infection was associated with higher concentrations of IL-6 (also, IL-6 concentrations in the 
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highest quartile), lower concentrations of d-dimer, and lower concentrations of HDL-c (also, 
having HDL-c concentrations that were not in the highest quartile). 
Using the PHQ-9 definition for symptoms of major depression, scores greater than or 
equal to ten were associated with higher concentrations of IL-6 and triglycerides in the standard 
multiple regression models adjusting for HIV, age, sex, and race/ethnicity (Table 4-7)  Only 
triglycerides were significantly higher in the fully adjusted models.  Logistic regression models 
were not significant for this measure of depression.  HIV infection remained significantly 
associated with higher concentrations of IL-6 and triglycerides and lower concentrations of d-
dimer, glucose, LDL-c, and HDL-c in these models.  In the fully adjusted models, HIV was 
associated with higher IL-6 and triglyceride concentrations and lower d-dimer and HDL-c 
concentrations. 
There were significant multiplicative interactions between HIV and MDD in their 
associations with sCD14 (p = 0.03), HDL-c (p = 0.01), and triglycerides (p = 0.02).  There were 
no significant multiplicative interactions between HIV and a PHQ-9 score ≥ 10.  In response to 
these interactions, we explored the associations between depression and biomarkers in models 
stratified by HIV status.   
In the HIV- participants, MDD was associated with higher concentrations of IL-6 and 
sCD14, adjusting for age, sex, and race/ethnicity (Table 4-8), while PHQ-9 scores ≥ 10 were 
associated with higher concentrations of IL-6 (Table 4-9).  These associations were no longer 
significant in the fully adjusted models (i.e., age, sex, race/ethnicity, SBP, DBP, BMI, smoking, 
HCV infection, and antidepressant use).   
In the HIV+ participants, MDD was associated with higher concentrations of glucose and 
lower concentrations of HDL-c, adjusting for age, sex, and race/ethnicity (Table 4-8), while 
 56 
PHQ-9 scores ≥ 10 were associated with higher concentrations of triglycerides (Table 4-9).  In 
the fully adjusted models, these associations were no longer significant, but MDD was associated 
with higher concentrations of sCD14 and interestingly, lower concentrations of IL-6. 
4.5 DISCUSSION 
In this study, we report that depression was associated with markers of inflammation and 
coagulation in the HIV- participants, but associated with markers of altered metabolism in the 
HIV+ participants, even after adjusting for BMI.  Our findings were consistent using two 
definitions of depression (a baseline medical record diagnosis of MDD and self-reported 
symptoms of depression using the PHQ-9). 
The finding that depression was significantly associated with IL-6 concentrations in HIV- 
participants is consistent with previous studies.  Two meta-analyses, which included results from 
over 60 studies, reported that depression or depressive symptoms were positively associated with 
higher concentrations of IL-6.1, 76  We found different results in the HIV+ participants.  Median 
concentrations of IL-6 were not significantly different with MDD or with PHQ-9 scores ≥ 10.  
This result is consistent with one previous study that found no significant association between 
depressive symptoms and IL-6 in HIV+ participants.85 
We found a significant association between MDD and higher concentrations of d-dimer 
in models adjusted for HIV, age, sex, and race/ethnicity, but the significance was lost in fully 
adjusted models. This finding supports previous studies that reported hypercoagulation with 
depression.77  In the adjusted models stratified by HIV status, depression was not associated with 
d-dimer.  HIV infection was associated with significantly lower concentrations of d-dimer.  
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Previous reports suggest that HIV is associated with higher concentrations of d-dimer when the 
viral infection is uncontrolled (HIV-RNA ≥ 500 copies/mL or CD4 count < 200 cells/µL).80  
Previous findings between depression and monocyte activation are limited and mixed.   
One study found no association between MDD and levels of sCD14 and one study found that 
monocytes reacted less in response to an endotoxin challenge in vitro.78, 86  In our study, the 
interaction between MDD and HIV was significant.  MDD was associated with increased 
concentrations of sCD14 in the HIV- participants in the stratified model.  There was no 
association in the HIV+ participants. 
In fully adjusted models of the total sample, MDD was associated with higher 
concentrations of glucose and HDL-c, while a PHQ-9 score ≥ 10 was associated with higher 
concentrations of triglycerides.  In stratified models, however, MDD and PHQ-9 scores ≥ 10 
were not associated with any metabolic marker in the HIV- group.  In the HIV+ participants, 
MDD was associated with an increased concentration of glucose and a decreased concentration 
of HDL-c, while PHQ-9 score ≥ 10 was associated with an increased concentration of 
triglycerides.  HIV infection was associated with lower concentrations of glucose, LDL-c, and 
HDL-c, and higher concentrations of triglycerides in models adjusted for depression, age, sex, 
and race/ethnicity. 
There are several limitations with this study.  First, most of the participants were males 
and the findings may not generalize to females.  Second, as our study is cross-sectional, we 
cannot determine directionality between depression and biomarker concentrations or causality.  
Third, our two definitions for depression had only fair agreement, which suggests that 
misclassification likely occurred.  The baseline MDD diagnosis may be a marker of a more 
chronic exposure to the unhealthy effects of depression, while the PHQ-9 score ≥10 describes 
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recent symptoms.  One explanation for this misclassification may be a result of effective MDD 
management.  Since majority of the participants with MDD were prescribed antidepressants 
during the baseline period, depressive symptoms may have been effectively managed over time, 
resulting in PHQ-9 scores less than 10 during their visit between 2005 and 2006.  Alternatively, 
participants may have developed MDD during the time period between April 1, 2003 and their 
visit between 2005 and 2006.  These participants would be falsely classified as MDD negative.  
Despite differences in these definitions, depression influenced biomarker concentrations in 
similar ways.  Last, biomarker concentrations were measured at a time point between 2005 and 
2006, while baseline characteristics and the MDD diagnosis were determined during the baseline 
period (1998 – 2003).  Biomarker concentrations may be influenced by more recent 
characteristics.  
We hypothesized that co-occurring depression and HIV infection, which have 
overlapping physiological mechanisms, would interact and result in exaggerated increases in 
biomarkers of inflammation, coagulation, monocyte activation, and altered metabolism.  Instead, 
our study provides new and interesting evidence that depression pathophysiology differs by HIV 
status.  These findings are important to both investigators and clinicians.  Studies that investigate 
the mechanism driving the association between depression and cardiovascular disease must 
consider co-occurring conditions, like HIV infection, in their analysis.  To address symptoms of 
depression and their implications with cardiovascular disease, clinicians may need to consider 
interventions that address inflammation in HIV- patients and metabolism in HIV+ patients. 
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4.6 TABLES AND FIGURES 
Table 4-1  Comparison between major depressive disorder and PHQ-9 Score ≥ 10 
 MDD No MDD Total Sample 
PHQ-9 score ≥ 10, n (%) 269 (12.8) 187 (8.9) 456 (21.7) 
PHQ-9 score < 10, n (%) 409 (19.5) 1,234 (58.8) 1,643 (78.3) 
Total sample 678 (32.3) 1,421 (67.7) 2,099 
Abbreviations:  MDD, major depressive disorder; PHQ-9, Patient Health Questionnaire – 9 item 
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Table 4-2  Prevalence of major depressive disorder and depressive symptom severity among the 
total sample and by HIV infection status 
  Total Sample 
(N = 2,099) 
HIV- 
(N = 734) 
HIV+ 
(N = 1,365) 
P 
value 
MDD, n (%) 678 (32.3) 252 (34.3) 426 (31.2) 0.14 
PHQ-9 Scores     
< 10, n (%) No major depression 1,643 (78.3) 546 (74.4) 1,097 (80.4) 0.002 
10 – 14, n (%) Mild major depression 214 (10.2) 78 (10.6) 136 (10.0) 0.63 
15 – 19, n (%) Moderate major depression 138 (6.6) 63 (8.6) 75 (5.5) 0.007 
≥ 20, n (%) Severe major depression  104 (5.0) 47 (6.4) 57 (4.2) 0.02 
Abbreviations:  HIV, human immunodeficiency virus; MDD, major depressive disorder; PHQ-9, 
Patient Health Questionnaire – 9 item 
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Table 4-3  Baseline participant characteristics by HIV status and major depressive disorder 
diagnosis (N = 2,099) 
HIV-uninfected HIV-infected 
 
No MDD MDD No MDD MDD 
Characteristic (n = 482) (n = 252) (n = 939) (n = 426) P 
Age, years, mean (SD) 54.7 (10.0) 51.9 (7.2) 51.9 (8.2) 51.8 (7.7) <.0001 
Male, % 90.0 88.9 97.2 96.5 <.0001 
African American, % 67.0 65.5 71.0 64.6 
0.2107 
     White, % 21.6 20.6 17.8 20.2 
     Hispanic, % 7.5 8.3 8.1 10.1 
     Other, % 3.9 5.6 3.1 5.2 
BMI, kg/m2, mean (SD) 30.3 (6.3) 29.6 (6.5) 25.7 (4.8) 26.2 (4.9) <.0001 
Systolic blood pressure, mean (SD) 132.0 (14.3) 130.8 (14.8) 128.0 (14.2) 129.3 (15.0) <.0001 
Diastolic blood pressure, mean (SD) 78.4 (9.4) 78.9 (10.4) 78.0 (9.0) 79.1 (9.6) 0.1801 
Diabetes mellitus, % 38.6 40.5 24.8 31.7 <.0001 
Statin use, % 15.4 15.5 12.8 17.4 0.1396 
Current smoking, % 40.2 64.0 48.5 55.2 
<.0001      Past, % 29.5 17.0 23.9 25.7 
     Never, % 30.3 19.0 27.6 19.1 
Alcohol abuse, % 35.9 66.3 29.9 55.9 <.0001 
Cocaine use, % 27.2 59.5 26.3 52.6 <.0001 




No MDD MDD No MDD MDD 
Characteristic (n = 482) (n = 252) (n = 939) (n = 426) P 
Any antidepressant use, % 13.1 54.8 15.6 54.7 <.0001 
     SSRI use, % 7.7 42.9 7.6 39.9 <.0001 
     TCA use, % 2.1 6.0 4.8 10.3 <.0001 
     Other antidepressant use, % 7.7 40.9 7.8 39.2 <.0001 
ART use, % -- -- 93.6 94.8 0.3773 

































Abbreviations:  ART, antiretroviral therapy; BMI, body mass index; HCV, hepatitis C virus; 
HDL, high-density lipoprotein; HIV, human immunodeficiency virus; MDD, major depressive 
disorder; SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressants 
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Table 4-3 Continued











(n = 482) 
MDD 
(n = 252) 
No MDD 
(n = 939) 
MDD 









N = 2064 
Median (IQR) 
> 75th percentile 
470 
1.67 (1.11, 2.87) 
21.3% 
245 





1.92 (1.37, 3.24) 
25.5% 
424 













N = 2070 
Median (IQR) 
> 75th percentile 
474 
0.29 (0.21, 0.50) 
24.9% 
246 





0.26 (0.15, 0.45) 
22.1% 
424 


















N = 2074 
Mean (SD) 






























N = 2093 
Median (IQR) 
> 75th percentile 
479 
100.0 (89.0, 115.0) 
28.8% 
250 





96.0 (87.0, 107.0) 
18.3% 
426 







N = 2035 
Mean (SD) 




















N = 2043 
Mean (SD) 




















N = 2065 
Median (IQR) 
> 75th percentile 
469 
120.0 (79.0, 174.0) 
17.9% 
245 





135.5 (88.0, 205.0) 
27.3% 
421 






Abbreviations:  HDL-c, high-density lipoprotein cholesterol; HIV, human immunodeficiency 
virus; IL-6, interleukin-6; LDL-c, low-density lipoprotein cholesterol; MDD, major depressive 
disorder; sCD14, soluble CD14 
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Table 4-5  Biomarker profiles by HIV status and symptoms of major depression (PHQ-9 ≥ 10) 









PHQ-9 < 10 
(n = 546) 
PHQ-9 ≥ 10 
 (n = 188) 
PHQ-9 < 10 
(n = 1097) 
PHQ-9 ≥ 10 









N = 2064 
Median (IQR) 
> 75th percentile 
534 
1.69 (1.13, 2.78) 
21.4% 
181 





1.98 (1.38, 3.28) 
26.0% 
266 













N = 2070 
Median (IQR) 
> 75th percentile 
538 
0.30 (0.21, 0.53) 
26.2% 
182 





0.26 (0.15, 0.47) 
23.1% 
265 


















N = 2074 
Mean (SD) 






























N = 2093 
Median (IQR) 
> 75th percentile 
541 
100.0 (89.0, 116.0) 
29.0% 
188 





96.0 (88.0, 109.0) 
21.0% 
268 







N = 2035 
Mean (SD) 




















N = 2043 
Mean (SD) 




















N = 2065 
Median (IQR) 
> 75th percentile 
530 
113.5 (75.0, 165.0) 
16.8% 
184 





135.0 (88.0, 203.0) 
26.9% 
264 






Abbreviations:  HDL-c, high-density lipoprotein cholesterol; HIV, human immunodeficiency 
virus; IL-6, interleukin-6; LDL-c, low-density lipoprotein cholesterol; PHQ-9, nine item Patient 
Health Questionnaire; sCD14, soluble CD14 
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Table 4-6  Association between major depressive disorder, HIV infection, and biomarker 
concentrations, in two models adjusting for covariates 
Table 4-6a IL-6 (N = 2064) D-dimer (N = 2070) 
Model 1 
β (95% CI) 
(continuous; log) 
OR (95% CI) 
(> 75th percentile) 
β (95% CI) 
(continuous; log) 
OR (95% CI) 
(> 75th percentile) 
MDD vs. no MDD 0.06 (-0.01, 0.13) 1.22 (0.98, 1.51) 0.09 (0.01, 0.18)* 1.26 (1.01, 1.56)* 
HIV+ vs. HIV- 0.14 (0.06, 0.21)* 1.24 (1.00, 1.54) -0.18 (-0.27, -0.10)* 0.94 (0.76, 1.17) 
Age (years) 0.01 (0.01, 0.02)* 1.03 (1.02, 1.04)* 0.02 (0.01, 0.02)* 1.04 (1.02, 1.05)* 
Sex -0.02 (-0.17, 0.14) 0.97 (0.61, 1.56) -0.06 (-0.24, 0.12) 1.29 (0.78, 2.13) 
White [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
 Black 0.04 (-0.05, 0.13) 1.08 (0.83, 1.40) 0.15 (0.05, 0.26)* 1.67 (1.26, 2.21)* 
 Hispanic 0.10 (-0.04, 0.24) 1.37 (0.92, 2.05) 0.05 (-0.11, 0.22) 1.31 (0.84, 2.04) 
 Other 0.16 (-0.02, 0.35) 1.02 (0.59, 1.79) 0.13 (-0.09, 0.35) 1.36 (0.76, 2.42) 
Table 4-6b IL-6 (N = 2042) D-dimer (N = 2048) 
Model 2 
β (95% CI) 
(continuous; log) 
OR (95% CI) 
(> 75th percentile) 
β (95% CI) 
(continuous; log) 
OR (95% CI) 
(> 75th percentile) 
MDD vs. no MDD -0.06 (-0.13, 0.02) 0.93 (0.73, 1.18) -0.01 (-0.10, 0.09) 1.02 (0.80, 1.31) 
HIV+ vs. HIV- 0.19 (0.12, 0.27)* 1.32 (1.04, 1.68)* -0.15 (-0.25, -0.06)* 1.02 (0.80, 1.29) 
Age (years) 0.02 (0.01, 0.02)* 1.04 (1.02, 1.05)* 0.02 (0.01, 0.02)* 1.04 (1.02, 1.05)* 
Sex -0.07 (-0.22, 0.08) 0.82 (0.51 1.32) -0.09 (-0.27, 0.10) 1.23 (0.74, 2.03) 
White [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
 Black -0.02 (-0.10, 0.07) 0.93 (0.71, 1.22) 0.12 (0.01, 0.22)* 1.56 (1.17, 2.09)* 
 Hispanic 0.06 (-0.08, 0.20) 1.30 (0.86, 1.95) 0.03 (-0.14, 0.20) 1.28 (0.82, 2.00) 
 Other 0.06 (-0.12, 0.24) 0.90 (0.51, 1.59) 0.10 (-0.13, 0.32) 1.25 (0.70, 2.25) 
BMI 0.02 (0.01, 0.02)* 1.03 (1.00, 1.05)* 0.005 (-0.002, 0.01) 1.01 (0.99, 1.03) 
Systolic blood pressure -0.002 (-0.005, 0.001) 1.00 (0.99, 1.01) 0.002 (-0.002, 0.006) 1.01 (1.00, 1.02) 
Diastolic blood pressure 0.003 (-0.002, 0.008) 1.01 (1.00, 1.03) -0.001 (-0.007, 0.005) 1.00 (0.98, 1.01) 
Diabetes 
Never smoking [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
 Current 0.18 (0.10, 0.27)* 1.69 (1.28, 2.23)* 0.13 (0.02, 0.23)* 1.25 (0.95, 1.64)* 
 Past -0.04 (-0.14, 0.06) 0.94 (0.69, 1.29) -0.05 (-0.17, 0.06) 0.96 (0.71, 1.31) 
HCV infection 0.12 (0.05, 0.19)* 1.31 (1.05, 1.64)* 0.01 (-0.08, 0.10) 0.97 (0.77, 1.21) 
Antidepressant Use 0.19 (0.10, 0.27)* 1.47 (1.15, 1.89)* 0.18 (0.08, 0.28)* 1.53 (1.19, 1.96)* 
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Table 4-6c sCD14 (N = 2074) Glucose (N = 2093) 
Model 1 
β (95% CI) 
(continuous) 
OR (95% CI) 
(> 75th percentile) 
β (95% CI) 
(continuous; log) 
OR (95% CI) 
(> 75th percentile) 
MDD vs. no MDD 29.7 (-18.2, 77.5) 1.15 (0.93, 1.42) 0.04 (0.01, 0.06)* 1.49 (1.20, 1.84)* 
HIV+ vs. HIV- 17.4 (-30.4, 65.2) 1.10 (0.89, 1.36) -0.03 (-0.05, -0.002)* 0.67 (0.54, 0.83)* 
Age (years) 6.03 (3.35, 8.71)* 1.02 (1.01, 1.03)* 0.005 (0.003, 0.006)* 1.04 (1.03, 1.05)* 
Sex -24.1 (-123.8, 75.7) 0.92 (0.59, 1.45) 0.01 (-0.04, 0.06) 1.10 (0.68, 1.76) 
White [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
 Black -85.0 (-142.8, -27.3)* 0.81 (0.63, 1.04) 0.003 (-0.03, 0.03) 1.03 (0.79, 1.35) 
 Hispanic -2.6 (-94.8, 89.5) 0.99 (0.66, 1.47) 0.03 (-0.02, 0.08) 1.72 (1.15, 2.56)* 
 Other -63.0 (-184.8, 58.9) 0.80 (0.46, 1.39) 0.05 (-0.02, 0.12) 1.24 (0.72, 2.14) 
Table 4-6d sCD14 (N = 2052) Glucose (N = 2074) 
Model 2 
β (95% CI) 
(continuous) 
OR (95% CI) 
(> 75th percentile) 
β (95% CI) 
(continuous; log) 
OR (95% CI) 
(> 75th percentile) 
MDD vs. no MDD -35.1 (-87.2, 17.1) 0.91 (0.72, 1.16) 0.02 (-0.006, 0.05) 1.39 (1.09, 1.77)* 
HIV+ vs. HIV- -42.9 (-93.8, 7.97) 0.88 (0.70, 1.12) 0.007 (-0.02, 0.03) 0.87 (0.69, 1.11) 
Age (years) 6.45 (3.65, 9.26)* 1.02 (1.01, 1.03)* 0.004 (0.003, 0.006)* 1.04 (1.02, 1.05)* 
Sex -55.3 (-154.1, 43.4) 0.82 (0.51, 1.29) 0.007 (-0.05, 0.06) 1.08 (0.67, 1.77) 
White [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
 Black -119.4 (-177.4, -61.3)* 0.72 (0.55, 0.93) -0.005 (-0.04, 0.03) 0.98 (0.74, 1.29) 
 Hispanic -16.4 (-107.5, 74.7) 0.94 (0.62, 1.40) 0.02 (-0.03, 0.07) 1.65 (1.10, 2.48)* 
 Other -65.0 (-186.0, 56.0) 0.77 (0.44, 1.35) 0.03 (-0.04, 0.09) 1.00 (0.57, 1.76) 
Systolic blood pressure -1.78 (-3.99, 0.43) 1.00 (0.99, 1.01) 0.002 (0.0003, 0.003)* 1.02 (1.01, 1.03)* 
Diastolic blood pressure 3.55 (0.23, 6.87) 1.01 (0.99, 1.02) -0.001 (-0.003, 0.001) 0.98 (0.97, 1.00)* 
BMI -8.77 (-13.1, -4.45)* 0.96 (0.94, 0.98)* 0.008 (0.006, 0.01)* 1.07 (1.05, 1.09)* 
Never smoking [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
 Current 60.6 (3.29, 118.0)* 1.56 (0.88, 1.51) -0.006 (-0.04, 0.02) 0.95 (0.72, 1.26) 
     Past -22.0 (-85.9, 42.0) 0.93 (0.69, 1.27) 0.01 (-0.02, 0.05) 1.14 (0.85, 1.54) 
HCV infection 88.2 (39.6, 136.8)* 1.41 (1.13, 1.76)* 0.03 (0.001, 0.05)* 1.32 (1.04, 1.66)* 
Antidepressant Use 114.1 (59.0, 169.2)* 1.49 (1.17, 1.90)* 0.02 (-0.007, 0.05) 1.17 (0.91, 1.51) 
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Table 4-6 Continued
Table 4-6e LDL-c (N = 2035) HDL-c (N = 2043) 
Model 1 
β (95% CI) 
(continuous) 
OR (95% CI) 
(> 75th percentile) 
β (95% CI) 
(continuous; log) 
OR (95% CI) 
(> 75th percentile) 
MDD vs. no MDD 0.20 (-3.03, 3.43) 0.96 (0.77, 1.20) -1.12 (-2.60, 0.36) 0.87 (0.70, 1.09) 
HIV+ vs. HIV- -5.51 (-8.73, -2.28)* 0.80 (0.65, 0.99)* -2.21 (-3.68, -0.74)* 0.91 (0.73, 1.13) 
Age (years) -0.27 (-0.45, -0.09)* 0.98 (0.97, 0.99)* 0.09 (0.008, 0.17)* 1.00 (1.00, 1.03)* 
Sex 1.26 (-5.48, 8.00) 1.06 (0.68, 1.66) -8.06 (-11.1, -5.00)* 0.40 (0.27, 0.61)* 
White [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
 Black -2.80 (-6.68, 1.08) 0.90 (0.69, 1.16) 6.49 (4.72, 8.26)* 2.04 (1.52, 2.74)* 
 Hispanic -7.76 (-13.9, -1.60)* 0.73 (0.47, 1.12) 2.19 (-0.63, 5.01) 0.96 (0.59, 1.58) 
 Other -12.4 (-20.6, -4.18)* 0.66 (0.37, 1.20) 1.59 (-2.18, 5.35) 1.08 (0.57, 2.04) 
Table 4-6f LDL-c (N = 2019) HDL-c (N = 2026) 
Model 2 
β (95% CI) 
(continuous) 
OR (95% CI) 
(> 75th percentile) 
β (95% CI) 
(continuous; log) 
OR (95% CI) 
(> 75th percentile) 
MDD vs. no MDD 3.94 (0.43, 7.45)* 1.21 (0.95, 1.55) -0.33 (-1.94, 1.28) 0.92 (0.71, 1.19) 
HIV+ vs. HIV- -1.50 (-4.93, 1.94) 0.97 (0.76, 1.23) -4.51 (-6.08, -2.94)* 0.64 (0.50, 0.82)* 
Age (years) -0.19 (-0.38, 0.0002) 0.98 (0.97, 0.99)* 0.07 (-0.02, 0.15) 1.01 (1.00, 1.03) 
Sex 3.34 (-3.30, 9.99) 1.21 (0.77, 1.90) -8.23 (-11.3, -5.20)* 0.37 (0.24, 0.56)* 
White [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
 Black -0.12 (-4.00, 3.76) 1.04 (0.80, 1.36) 6.43 (4.65, 8.20)* 1.98 (1.46, 2.68)* 
 Hispanic -5.47 (-11.5, 0.60) 0.81 (0.52, 1.25) 2.60 (-0.18, 5.39) 1.00 (0.60, 1.66) 
 Other -11.2 (-19.3, -3.01)* 0.72 (0.40, 1.33) 2.94 (-0.79, 6.68) 1.22 (0.63, 2.37) 
Systolic blood pressure -0.04 (-0.18, 0.11) 1.00 (0.99, 1.01) 0.06 (-0.01, 0.12) 1.01 (1.00, 1.02) 
Diastolic blood pressure 0.17 (-0.05, 0.39) 1.00 (0.99, 1.02) -0.004 (-0.11, 0.10) 1.00 (0.57, 1.02) 
BMI 0.40 (0.12, 0.69)* 1.02 (1.00, 1.04)* -0.61 (-0.74, -0.48)* 0.90 (0.88, 0.93)* 
Never smoking [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
  Current -0.67 (-4.52, 3.18) 0.92 (0.70, 1.19) -0.96 (-2.73, 0.80) 0.95 (0.72, 1.25) 
     Past -0.28 (-4.55, 4.00) 1.03 (0.78, 1.38) -1.44 (-3.40, 0.52) 0.82 (0.60, 1.13) 
HCV infection -13.3 (-16.6, -10.0)* 0.49 (0.39, 0.62)* -0.58 (-2.08, 0.91) 0.95 (0.75, 1.20) 
Antidepressant Use -4.48 (-8.18, -0.77)* 0.75 (0.57, 0.98)* -1.52 (-3.22, 0.18) 0.87 (0.66, 1.14) 
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Table 4-6 Continued
Table 4-6g Triglyceride (N = 2065) 
Model 1 
β (95% CI) 
(continuous) 
OR (95% CI) 
(> 75th percentile) 
MDD vs. no MDD 0.01 (-0.04, 0.07) 1.05 (0.84, 1.31) 
HIV+ vs. HIV- 0.18 (0.13, 0.24)* 1.92 (1.52, 2.44) 
Age (years) -0.00001 (-0.003, 0.003) 1.00 (0.99, 1.02) 
Sex 0.13 (0.007, 0.25)* 1.48 (0.86, 2.54) 
White [Reference] 1.00 [Reference] 
 Black -0.26 (-0.33, -0.19)* 0.46 (0.36, 0.59) 
 Hispanic -0.03 (-0.14, 0.08) 0.96 (0.66, 1.41) 
 Other -0.06 (-0.21, 0.09) 0.92 (0.55, 1.54) 
Table 4-6h Triglyceride (N = 2049) 
Model 2 
β (95% CI) 
(continuous) 
OR (95% CI) 
(> 75th percentile) 
MDD vs. no MDD -0.02 (-0.08, 0.04) 0.96 (0.75, 1.22) 
HIV+ vs. HIV- 0.28 (0.22, 0.34)* 2.45 (1.88, 3.18)* 
Age (years) 0.001 (-0.003, 0.004) 1.00 (0.99, 1.02) 
Sex 0.12 (-0.001, 0.24)* 1.44 (0.83, 2.49) 
White [Reference] 1.00 [Reference] 
 Black -0.27 (-0.34, -0.20)* 0.43 (0.33, 0.56)* 
 Hispanic -0.04 (-0.15, 0.06) 0.92 (0.63, 1.35) 
 Other -0.14 (-0.29, 0.005) 0.76 (0.45, 1.29) 
Systolic blood pressure -0.002 (-0.004, 0.001)* 1.00 (0.99, 1.01) 
Diastolic blood pressure 0.006 (0.002, 0.01)* 1.02 (1.00, 1.03) 
BMI 0.02 (0.02, 0.03)* 1.05 (1.03, 1.08)* 
Never smoking [Reference] 1.00 [Reference] 
 Current 0.01 (-0.06, 0.08) 1.08 (0.82, 1.42) 
     Past 0.07 (-0.003, 0.15) 1.24 (0.92, 1.67) 
HCV infection 0.04 (-0.02, 0.09) 1.12 (0.89, 1.41) 
Antidepressant Use 0.05 (-0.02, 0.11) 1.14 (0.88, 1.48) 
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Table 4-6 Continued
Table 4-7  Association between symptoms of major depression (PHQ-9 ≥ 10), HIV infection, 
and biomarker concentrations, in two models adjusting for covariates 
Table 4-7a IL-6 (N = 2064) D-dimer (N = 2070) 
Model 1 
β (95% CI) 
(continuous; log) 
OR (95% CI) 
(> 75th percentile) 
β (95% CI) 
(continuous; log) 
OR (95% CI) 
(> 75th percentile) 
PHQ-9 ≥ 10 vs. < 10 0.09 (0.01, 0.17)* 1.17 (0.92, 1.49) 0.06 (-0.04, 0.16) 1.12 (0.87, 1.44) 
HIV+ vs. HIV- 0.14 (0.07, 0.21)* 1.24 (1.00, 1.55) -0.18 (-0.27, -0.10)* 0.94 (0.76, 1.17) 
Age (years) 0.01 (0.01, 0.02)* 1.03 (1.02, 1.04)* 0.02 (0.01, 0.02)* 1.04 (1.02, 1.05)* 
Sex -0.02 (-0.17, 0.14) 0.97 (0.61, 1.56) -0.06 (-0.24, 0.12) 1.29 (0.78, 2.12) 
White [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
 Black 0.04 (-0.05, 0.13) 1.08 (0.83, 1.41) 0.15 (0.05, 0.26)* 1.66 (1.25, 2.20)* 
 Hispanic 0.10 (-0.04, 0.24) 1.37 (0.92, 2.05) 0.05 (-0.12, 0.22) 1.31 (0.84, 2.04) 
 Other 0.17 (-0.02, 0.35) 1.04 (0.59, 1.81) 0.14 (-0.08, 0.36) 1.38 (0.78, 2.45) 
Table 4-7b IL-6 (N = 2042) D-dimer (N = 2048) 
Model 2 
β (95% CI) 
(continuous; log) 
OR (95% CI) 
(> 75th percentile) 
β (95% CI) 
(continuous; log) 
OR (95% CI) 
(> 75th percentile) 
PHQ-9 ≥ 10 vs. < 10 0.005 (-0.08, 0.09) 0.95 (0.74, 1.22) -0.001 (-0.10, 0.10) 0.98 (0.75, 1.27) 
HIV+ vs. HIV- 0.19 (0.12, 0.27)* 1.32 (1.04, 1.68)* -0.15 (-0.25, -0.06)* 1.01 (0.80, 1.28) 
Age (years) 0.02 (0.01, 0.02)* 1.04 (1.02, 1.05)* 0.02 (0.01, 0.02)* 1.04 (1.02, 1.05)* 
Sex -0.07 (-0.22, 0.08) 0.82 (0.51, 1.32) -0.09 (-0.27, 0.10) 1.22 (0.74, 2.03) 
White [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
 Black -0.01 (-0.10, 0.08) 0.93 (0.71, 1.22) 0.12 (0.01, 0.22)* 1.56 (1.17, 2.08)* 
 Hispanic 0.06 (-0.08, 0.20) 1.30 (0.86, 1.95) 0.03 (-0.14, 0.20) 1.28 (0.82, 2.00) 
 Other 0.06 (-0.12, 0.24) 0.90 (0.51, 1.59) 0.10 (-0.13, 0.32) 1.25 (0.70, 2.25) 
Systolic blood pressure -0.002 (-0.005, 0.001) 1.00 (0.99, 1.01) 0.002 (-0.002, 0.006) 1.01 (1.00, 1.02) 
Diastolic blood pressure 0.003 (-0.002, 0.008) 1.01 (1.00 1.03) -0.001 (-0.007, 0.005) 1.00 (0.98, 1.01) 
BMI 0.02 (0.01, 0.02)* 1.03 (1.00, 1.05)* 0.005 (-0.003, 0.01) 1.01 (0.99, 1.03) 
Never smoking [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
 Current 0.18 (0.09, 0.26)* 1.69 (1.28, 2.23)* 0.13 (0.02, 0.23)* 1.25 (0.95, 1.65) 
     Past -0.04 (-0.14, 0.05) 0.94 (0.68, 1.29) -0.05 (-0.17, 0.06) 0.96 (0.71, 1.31) 
HCV infection 0.12 (0.04, 0.19)* 1.31 (1.05, 1.64)* 0.01 (-0.08, 0.10) 0.97 (0.77, 1.22) 
Antidepressant Use 0.16 (0.08, 0.24)* 1.44 (1.15, 1.81)* 0.18 (0.09, 0.28)* 1.55 (1.23, 1.96)* 
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Table 4-7c sCD14 (N = 2074) Glucose (N = 2093) 
Model 1 
β (95% CI) 
(continuous) 
OR (95% CI) 
(> 75th percentile) 
β (95% CI) 
(continuous; log) 
OR (95% CI) 
(> 75th percentile) 
PHQ-9 ≥ 10 vs. < 10 14.2 (-40.5, 69.0) 1.03 (0.81, 1.32) 0.002 (-0.03, 0.03) 1.13 (0.88, 1.45) 
HIV+ vs. HIV- 17.4 (-30.5, 65.2) 1.10 (0.88, 1.36) -0.03 (-0.06, -0.003)* 0.67 (0.54, 0.83)* 
Age (years) 6.00 (3.11, 8.68)* 1.02 (1.01, 1.03)* 0.005 (0.003, 0.006)* 1.04 (1.03, 1.05)* 
Sex -24.4 (-124.2, 75.5) 0.92 (0.59, 1.44) 0.01 (-0.04, 0.06) 1.09 (0.68, 1.75) 
White [Reference] 1.00 [Reference]  [Reference] 1.00 [Reference] 
 Black -85.1 (-143.0, -27.2)* 0.81 (0.63, 1.04) 0.001 (-0.03, 0.03) 1.02 (0.79, 1.34) 
 Hispanic -2.60 (-94.8, 89.6) 0.99 (0.66, 1.47) 0.03 (-0.02, 0.08) 1.72 (1.16, 2.56)* 
 Other -60.8 (-182.7, 61.0) 0.81 (0.47, 1.04) 0.05 (-0.01, 0.12) 1.27 (0.74, 2.19) 
Table 4-7d sCD14 (N = 2052) Glucose (N = 2074) 
Model 2 
β (95% CI) 
(continuous) 
OR (95% CI) 
(> 75th percentile) 
β (95% CI) 
(continuous; log) 
OR (95% CI) 
(> 75th percentile) 
PHQ-9 ≥ 10 vs. < 10 -25.9 (-81.4, 29.7) 0.91 (0.71, 1.18) -0.01 (-0.04, 0.02) 1.01 (0.78, 1.31) 
HIV+ vs. HIV- -43.2 (-94.1, 7.75) 0.88 (0.70, 1.11) 0.005 (-0.02, 0.03) 0.87 (0.69, 1.10) 
Age (years) 6.47 (3.66, 9.28)* 1.02 (1.01, 1.03)* 0.004 (0.003, 0.006)* 1.04 (1.02, 1.05)* 
Sex -54.7 (-153.5, 44.1) 0.82 (0.51, 1.29) 0.005 (-0.05, 0.06) 1.07 (0.65, 1.74) 
White [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
 Black -119.4 (-177.6, -61.2)* 0.72 (0.55, 0.93)* -0.008 (-0.04, 0.02) 0.95 (0.72, 1.26) 
 Hispanic -15.7 (-106.8, 75.4) 0.94 (0.62, 1.41) 0.02 (-0.03, 0.07) 1.64 (1.09, 2.46)* 
 Other -65.5 (-186.5, 55.6) 0.77 (0.44, 1.35) 0.03 (-0.04, 0.09) 1.00 (0.57, 1.76) 
Systolic blood pressure -1.81 (-4.02, 0.40) 1.00 (0.98, 1.01) 0.001 (0.0003, 0.003)* 1.02 (1.01, 1.03)* 
Diastolic blood pressure 3.55 (0.23, 6.87)* 1.01 (0.99, 1.02) -0.0006 (-0.002, 0.001) 0.99 (0.97, 1.00)* 
BMI -8.73 (-13.1, -4.39)* 0.96 (0.94, 0.98)* 0.009 (0.006, 0.01)* 1.07 (1.05, 1.09)* 
Never smoking [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
 Current 59.6 (2.20, 116.9)* 1.15 (0.88, 1.51) -0.003 (-0.03, 0.03) 0.97 (0.74, 1.29) 
     Past -23.7 (-87.7, 40.2) 0.93 (0.68, 1.26) 0.01 (-0.02, 0.05) 1.15 (0.86, 1.55) 
HCV infection 88.1 (39.5, 136.8)* 1.41 (1.13, 1.76)* 0.03 (0.003, 0.06)* 1.33 (1.06, 1.68)* 
Antidepressant Use 103.8 (52.3, 155.2)* 1.46 (1.16, 1.83)* 0.03 (0.006, 0.06)* 1.34 (1.06, 1.70)* 
71 
Table 4-7 Continued
Table 4-7e LDL-c (N = 2035) HDL-c (N = 2043) 
Model 1 
β (95% CI) 
(continuous) 
OR (95% CI) 
(> 75th percentile) 
β (95% CI) 
(continuous; log) 
OR (95% CI) 
(> 75th percentile) 
PHQ-9 ≥ 10 vs. < 10 -3.29 (-6.98, 0.39) 0.90 (0.70, 1.16) -0.83 (-2.52, 0.85) 1.08 (0.84, 1.39) 
HIV+ vs. HIV- -5.73 (-8.97, -2.50)* 0.80 (0.64, 0.99)* -2.23 (-3.70, -0.75)* 0.92 (0.73, 1.14) 
Age (years) -0.28 (-0.46, -0.10)* 0.98 (0.97, 0.99)* 0.09 (0.008, 0.17)* 1.02 (1.00, 1.03)* 
Sex 1.13 (-5.61, 7.86) 1.06 (0.68, 1.65) -8.06 (-11.1, -5.00)* 0.41 (0.27, 0.61)* 
White [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
 Black -3.03 (-6.91, 0.86) 0.89 (0.69, 1.16) 6.48 (4.70, 8.25)* 2.06 (1.54, 2.77)* 
 Hispanic -7.61 (-13.8, -1.45)* 0.73 (0.48, 1.24) 2.21 (-0.61, 5.03) 0.95 (0.58, 1.57) 
 Other -12.3 (-20.5, -4.07)* 0.66 (0.37, 1.20) 1.51 (-2.26, 5.27) 1.06 (0.56, 2.01) 
Table 4-7f LDL-c (N = 2019) HDL-c (N = 2026) 
Model 2 
β (95% CI) 
(continuous) 
OR (95% CI) 
(> 75th percentile) 
β (95% CI) 
(continuous; log) 
OR (95% CI) 
(> 75th percentile) 
PHQ-9 ≥ 10 vs. < 10 -1.45 (-5.18, 2.28) 1.03 (0.79, 1.34) 0.03 (-1.67, 1.74) 1.21 (0.92, 1.58) 
HIV+ vs. HIV- -1.66 (-5.10, 1.78) 0.97 (0.76, 1.23) -4.50 (-6.07, -2.93)* 0.65 (0.51, 0.83)* 
Age (years) -0.20 (-0.39, -0.01)* 0.98 (0.97, 0.99)* 0.07 (-0.02, 0.15) 1.01 (1.00, 1.03) 
Sex 3.05 (-3.61, 9.70) 1.20 (0.76, 1.89) -8.21 (-11.2, -5.18)* 0.37 (0.24, 0.57)* 
White [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
 Black -0.54 (-4.43, 3.35) 1.03 (0.79, 1.35) 6.45 (4.67, 8.24)* 2.02 (1.49, 2.74)* 
 Hispanic -5.49 (-11.6, 0.59) 0.80 (0.52, 1.24) 2.61 (-0.18, 5.39) 1.00 (0.60, 1.66) 
 Other -11.1 (-19.3, -2.99)* 0.72 (0.40, 1.33) 2.94 (-0.80, 6.68) 1.22 (0.63, 2.37) 
Systolic blood pressure -0.04 (-0.19, 0.11) 1.00 (0.99, 1.01) 0.06 (-0.01, 0.12) 1.01 (1.00, 1.02) 
Diastolic blood pressure 0.18 (-0.04, 0.41) 1.00 (0.99, 1.02) -0.005 (-0.11, 0.10) 1.00 (0.99, 1.02) 
BMI 0.43 (0.14, 0.72)* 1.02 (1.00, 1.04)* -0.61 (-0.74, -0.48)* 0.90 (0.88, 0.92)* 
Never smoking [Reference] 1.00 [Reference] [Reference] 1.00 [Reference] 
 Current -0.23 (-4.08, 3.63) 0.93 (0.72, 1.21) -0.99 (-2.76, 0.77) 0.93 (0.70, 1.22) 
     Past -0.09 (-4.37, 4.18) 1.05 (0.78, 1.40) -1.46 (-3.42, 0.50) 0.82 (0.60, 1.13) 
HCV infection -13.1 (-16.3, -9.80)* 0.49 (0.39, 0.62)* -0.60 (-2.10, 0.90) 0.93 (0.74, 1.18) 
Antidepressant Use -2.61 (-6.07, 0.85) 0.81 (0.63, 1.04) -1.66 (-3.25, -0.08)* 0.82 (0.63, 1.05) 
72 
Table 4-7 Continued
Table 4-7g Triglyceride (N = 2065) 
Model 1 
β (95% CI) 
(continuous) 
OR (95% CI) 
(> 75th percentile) 
PHQ-9 ≥ 10 vs. < 10 0.10 (0.04, 0.17)* 1.27 (0.99, 1.62) 
HIV+ vs. HIV- 0.19 (0.13, 0.25)* 1.95 (1.54, 2.48)* 
Age (years) 0.0004 (-0.003, 0.004) 1.01 (0.99, 1.02) 
Sex 0.13 (0.01, 0.25)* 1.48 (0.86, 2.55) 
White [Reference] 1.00 [Reference] 
 Black -0.26 (-0.32, -0.19)* 0.47 (0.36, 0.60)* 
 Hispanic -0.03 (-0.14, 0.08) 0.96 (0.65, 1.40) 
 Other -0.06 (-0.21, 0.08) 0.91 (0.54, 1.53) 
Table 4-7h Triglyceride 
Model 2 
β (95% CI) 
(continuous) 
OR (95% CI) 
(> 75th percentile) 
PHQ-9 ≥ 10 vs. < 10 0.08 (0.01, 0.14)* 1.17 (0.91, 1.52) 
HIV+ vs. HIV- 0.28 (0.22, 0.35)* 2.46 (1.90, 3.20)* 
Age (years) 0.001 (-0.002, 0.004) 1.01 (0.99, 1.02) 
Sex 0.12 (0.005, 0.24)* 1.45 (0.84, 2.51) 
White [Reference] 1.00 [Reference] 
 Black -0.27 (-0.33, -0.20)* 0.44 (0.34, 0.57)* 
 Hispanic -0.04 (-0.15, 0.06) 0.92 (0.63, 1.35) 
 Other -0.14 (-0.29, 0.005) 0.76 (0.45, 1.29) 
Systolic blood pressure -0.002 (-0.004, 0.001) 1.00 (0.99, 1.01) 
Diastolic blood pressure 0.005 (0.002, 0.009)* 1.02 (1.00, 1.03) 
BMI 0.02 (0.02, 0.03)* 1.05 (1.03, 1.07)* 
Never smoking [Reference] 1.00 [Reference] 
 Current 0.002 (-0.07, 0.07) 1.07 (0.81, 1.40) 
     Past 0.07 (-0.004, 0.15) 1.24 (0.92, 1.66) 
HCV infection 0.03 (-0.03, 0.09) 1.11 (0.89, 1.40) 
Antidepressant Use 0.02 (-0.04, 0.09) 1.09 (0.86, 1.39) 
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Table 4-8  Association between MDD and biomarker concentrations by HIV status 
IL-6 (N = 2064) D-dimer (N = 2070) 
Model 1 Model 2 Model 1 Model 2 
HIV- 0.17 (0.04, 0.30)* 0.06 (-0.08, 0.20) 0.11 (-0.02, 0.23) 0.003 (-0.13, 0.14) 
HIV+ 0.006 (-0.08, 0.09) -0.10 (-0.19, -0.01)* 0.10 (-0.02, 0.21) 0.02 (-0.11, 0.14) 
sCD14 (N = 2074) Glucose (N = 2093) 
Model 1 Model 2 Model 1 Model 2 
HIV- 108.9 (34.9, 182.9)* 25.3 (-55.3, 106.0) 0.007 (-0.04, 0.05) 0.001 (-0.05, 0.05) 
HIV+ -15.9 (-77.9, 46.2) -61. 8 (-129.2, 5.52) 0.05 (0.02, 0.08)* 0.03 (-0.003, 0.06) 
LDL-c (N = 2035) HDL-c (N = 2043) 
Model 1 Model 2 Model 1 Model 2 
HIV- 1.68 (-3.84, 7.21) 5.68 (-0.45, 11.8) 1.43 (-0.91, 3.76) 2.08 (-0.47, 4.63) 
HIV+ -1.12 (-5.12, 2.88) 1.96 (-2.33, 6.24) -2.61 (-4.50, -0.71)* -1.69 (-3.75, 0.38) 
Triglycerides (N = 2065) 
Model 1 Model 2 
HIV- -0.09 (-0.19, 0.003) -0.07 (-0.18, 0.03) 
HIV+ 0.06 (-0.01, 0.13) 0.006 (-0.07, 0.84) 
Model 1: Adjusted for age, sex, and race/ethnicity;  
Model 2: Adjusted for age, sex, race/ethnicity, SBP, DBP, BMI, smoking, HCV, and 
antidepressants 
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Table 4-9  Association between symptoms of major depression (PHQ-9 ≥ 10) and biomarker 
concentrations by HIV status 
IL-6 D-dimer 
Model 1 Model 2 Model 1 Model 2 
HIV- 0.19 (0.05, 0.33)* 0.08 (-0.06, 0.22) 0.02 (-0.11, 0.16) -0.03 (-0.18, 0.11) 
HIV+ 0.02 (-0.08, 0.12) -0.05 (-0.15, 0.05) 0.09 (-0.05, 0.22) 0.03 (-0.11, 0.17) 
sCD14 Glucose 
Model 1 Model 2 Model 1 Model 2 
HIV- 46.8 (-34.8, 128.3) -16.0 (-99.0, 67.0) 0.02 (-0.03, 0.07) 0.01 (-0.04, 0.06) 
HIV+ -9.11 (-81.8, 63.6) -35.5 (-108.9, 38.0) -0.01 (-0.05, 0.02) -0.03 (-0.07, 0.007) 
LDL-c HDL-c 
Model 1 Model 2 Model 1 Model 2 
HIV- -5.66 (-11.7, 0.34) -3.93 (-10.2, 2.31) 0.13 (-2.41, 2.67) 0.67 (-1.93, 3.26) 
HIV+ -1.91 (-6.60, 2.77) -0.16 (-4.83, 4.51) -1.57 (-3.79, 0.66) -0.57 (-2.82, 1.68) 
Triglycerides 
Model 1 Model 2 
HIV- 0.06 (-0.04, 0.17) 0.07 (-0.03, 0.18) 
HIV+ 0.12 (0.03, 0.20)* 0.08 (-0.008, 0.16) 
Model 1: Adjusted for age, sex, and race/ethnicity;  
Model 2: Adjusted for age, sex, race/ethnicity, SBP, DBP, BMI, smoking, HCV, and 
antidepressants 
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Table 4-10  Supplemental Table.  Baseline participant characteristics by HIV status and 
symptoms of major depression (PHQ-9 ≥ 10) (N = 2,099) 
HIV-uninfected HIV-infected 
 
PHQ-9 < 10 PHQ-9 ≥ 10 PHQ-9 < 10 PHQ-9 ≥ 10 
Characteristic (n = 546) (n = 188) (n = 1097) (n = 268) P 
Age, years, mean (SD) 54.5 (9.7) 51.7 (7.5) 52.0 (8.1) 51.1 (7.6) <.0001 
Male, % 90.8 86.2 96.8 97.8 <.0001 
African American, % 68.9 59.6 70.9 61.2 
0.0138 
     White, % 20.2 24.5 17.9 21.3 
     Hispanic, % 6.8 10.6 7.8 12.3 
     Other, % 4.2 5.3 3.4 5.2 
BMI, kg/m2, mean (SD) 29.8 (6.1) 30.6 (7.0) 25.7 (4.9) 26.4 (4.5) <.0001 
Systolic BP, mean (SD) 132.3 (14.6) 129.3 (13.7) 128.2 (14.4) 129.1 (14.5) <.0001 
Diastolic BP, mean (SD) 78.6 (9.9) 78.3 (9.6) 78.0 (9.0) 79.6 (9.8) 0.0959 
Diabetes mellitus, % 38.1 42.6 27.4 25.4 <.0001 
Statin use, % 14.3 18.6 14.3 13.8 0.4437 
Current smoking, % 43.0 63.9 49.0 57.1 
<.0001      Past, % 28.9 14.2 24.8 23.1 
     Never, % 28.0 21.9 26.2 19.8 
Alcohol abuse, %  42.5 57.5 34.8 51.1 <.0001 
Cocaine use, %  35.0 47.9 31.9 45.2 <.0001 




PHQ-9 < 10 PHQ-9 ≥ 10 PHQ-9 < 10 PHQ-9 ≥ 10 
Characteristic (n = 546) (n = 188) (n = 1097) (n = 268) P 
Any antidepressant use, % 21.6 44.2 23.6 44.8 <.0001 
     SSRI use, % 14.5 35.1 14.0 32.5 <.0001 
     TCA use, % 2.9 4.8 5.5 10.8 <.0001 
     Other antidepressant use, % 14.5 32.5 14.6 29.9 <.0001 
ART use, % -- -- 93.6 94.8 0.2634 

































Abbreviations:  ART, antiretroviral therapy; BMI, body mass index; HCV, hepatitis C virus; 
HDL, high-density lipoprotein; HIV, human immunodeficiency virus; MDD, major depressive 
disorder; SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressants 
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Table 4-11  Supplemental Table 1.  Exploring major depressive disorder and treatment; 





No MDD Total Sample 
PHQ-9 score ≥ 10, n (%) 111 (19.3) 158 (17.3) 187 (13.2) 456 (21.7) 
PHQ-9 score < 10, n (%) 196 (80.8) 213 (82.8) 1,234 (86.8) 1,643 (78.3) 
Total sample 307 (14.6) 371 (17.7) 1,421 (67.7) 2,099 
Abbreviations:  MDD, major depressive disorder; PHQ-9, Patient Health Questionnaire – 9 item 
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Figure 4-1.  Timeline of independent and dependent variables 
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5.0  BIOMARKER PROFILE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN 
VETERANS WITH AND WITHOUT HIV INFECTION 
Jessica R. White, MS; Department of Epidemiology, University of Pittsburgh Graduate School 
of Public Health, Pittsburgh, PA, USA; Chung-Chou H. Chang, PhD; Division of General 
Internal Medicine, Department of Medicine, University of Pittsburgh School of Medicine, 
Pittsburgh, PA, USA; Department of Biostatistics, University of Pittsburgh Graduate School of 
Public Health, Pittsburgh, PA, USA; Kaku A. So-Armah, PhD; Department of Internal 
Medicine, Yale University, New Haven, CT, USA; Amy C. Justice, MD, MSCE, PhD; Yale 
University School of Medicine, New Haven, CT; Veterans Affairs Connecticut Health Care 
System, West Haven Veterans Administration Medical Center, West Haven, CT, USA; and 
Matthew S. Freiberg, MD, MPH;  Cardiovascular Medicine Division, Vanderbilt University 




BACKGROUND:  Depressive symptoms are associated with systemic biochemical changes. 
These changes can be detected by measuring concentrations of growth factors, markers of 
inflammation, endocrine markers, and metabolic markers in peripheral blood.  We provide 
biomarker profiles associated with depressive symptoms in HIV positive and HIV negative 
veterans. 
METHODS:  We analyzed data from participants enrolled in the Veterans Aging Cohort Study 
(VACS), a large prospective cohort of HIV+ and HIV- veterans matched by age, sex, 
race/ethnicity, and geographical region.  This study included 303 participants from the Three Site 
Cardiovascular Disease Substudy who completed the nine item Patient Health Questionnaire 
(PHQ-9).  We used linear regression to determine whether self-reported symptoms of major 
depression, defined as PHQ-9 ≥ 10, were associated with decreased growth factor concentration 
and increased inflammatory markers, endocrine markers, and metabolic markers in both the 
HIV- and HIV+ participants. 
RESULTS:  This sample included 63 (20.8%) participants with symptoms of major depression, 
and there was no significant difference in depressive symptom severity by HIV status.  Age and 
body mass index (BMI) varied significantly across the HIV/depression groups.  In HIV- 
participants, triglyceride concentrations were significantly higher among those with depression 
compared to those without depression.  In HIV+ participants, depression was associated with 
significantly lower concentrations of VEGF and significantly higher concentrations of leptin.  In 
models adjusted for age, race/ethnicity, and BMI, depression was associated with glucose, LDL-
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c, and triglyceride concentrations in HIV- participants, and leptin in HIV+ participants.  In 
exploratory analysis, depression was associated with metabolic syndrome in HIV- participants. 
CONCLUSIONS:  Our study is the first to provide an extensive biomarker profile for individuals 
with and without depressive symptoms in a cohort of HIV- and HIV+ veterans.  We found 
significant changes in a few metabolic markers with symptoms of major depression and these 
changes varied by HIV status.  Future studies may use these findings to determine whether these 
biomarkers mediate the association between depression and cardiovascular diseae. 
5.2 INTRODUCTION 
Depressive symptoms are associated with systemic changes that can be quantified by biomarkers 
in peripheral blood.4  Schmidt, et al. (2011) identified four sets of biomarkers that warrant 
further investigation in studies of depression: growth factors, markers of inflammation, 
endocrine markers, and metabolic markers.  Pathological concentrations of these biomarkers are 
associated with cardiovascular disease (CVD) and death.87 
HIV infection is also associated with these biomarkers and CVD events.80  We recently 
provided evidence that major depressive disorder (MDD) is associated myocardial infarction and 
heart failure in both HIV negative (HIV-) and HIV positive (HIV+) veterans, and that the risk for 
incident cardiovascular disease events were highest in those with co-occurring HIV and 
depression.74, 75  The mechanisms related to these associations remain unexplained.  Yet, it stands 
to reason, that the altered concentrations of growth factors, cytokines, endocrine markers, and 
metabolic factors observed with depression may be important for driving the excess 
cardiovascular risk with co-occurring depression and HIV infection. 
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We had a unique opportunity to explore biomarker profiles in a cohort of HIV+ and HIV- 
veterans who reported their depressive symptoms.  Our aim was to determine whether depression 
was associated with changes in concentrations in concentrations of growth factors, cytokines, 
endocrine markers, and metabolic factors in both HIV+ and HIV- veterans.  We hypothesized 
that symptoms of major depression were associated with (1) lower concentrations of growth 
factors, (2) higher concentrations of inflammatory makers, (3) higher concentrations of 
endocrine markers, and (4) higher concentrations of metabolic biomarkers compared to those 
without symptoms of major depression.  We also hypothesized that the biomarker profiles would 
show different trends in HIV- participants compared to those with HIV infection. 
5.3 METHODS 
Participants 
The Veterans Aging Cohort Study (VACS) is a large prospective study of HIV+ and 
HIV- veterans who were matched 1:2 by age, sex, race/ethnicity and geographical region during 
the same enrollment year from the US Department of Veterans Affairs (VA) system.  Details 
about the study participants have been published previously.50  For this analysis, we used data 
from the VACS Three Site CVD Study, a subset of over 300 VACS participants who completed 
a series of questionnaires and provided blood samples for in depth peripheral blood analysis. 
Participants with acute myocardial infarction, unstable angina, heart failure, stroke or transient 
ischemic attack, peripheral vascular disease, or cardiovascular revascularization diagnosis on or 
before their baseline enrollment date were excluded from this analysis.  The baseline enrollment 
period was between 2009 – 2013.  These conditions were determined using International 
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Classification of Diseases, Ninth Revision (ICD-9) codes from their VA medical records.  This 
study was approved by Institutional Review Boards at the University of Pittsburgh, Yale 
University, and West Haven VA Medical Center and participants provided written informed 
consent. 
Independent Variables 
Participants were classified as HIV+ if their medical record included at least one inpatient 
ICD-9 code for HIV infection and/or at least two outpatient ICD-9 codes for HIV infection at the 
time of enrollment.  This algorithm was developed in the original VACS analyses and has been 
shown to have high sensitivity (90%), specificity (99.9%), and positive predictive value (88%).50 
We examined depressive symptoms using the nine-item Patient Health Questionnaire 
(PHQ-9).82  The PHQ-9 is a self-report questionnaire that assesses depressive symptoms over the 
preceding two weeks.88  Cumulative scores range from 0 (least severe) to 27 (most severe). 
Using a score of 10 or higher on the PHQ-9, the sensitivity and specificity for the predicting 
MDD in the primary care population is 74% and 91%, respectively.83  The PHQ-9 has been 
validated in HIV+ participants.89  Since a meaningful PHQ-9 score requires a sum of scores from 
all nine items, we excluded participants who did complete all of the questions. 
Four PHQ-9 score cut-points have been established to classify depression symptom 
severity.  These include: no major depression (PHQ-9 < 10); mild major depression (PHQ-9 10 
– 14); moderate major depression (PHQ-9 15 – 19); and severe major depression (PHQ-9 ≥ 20).
Dependent Variables 
Biomarkers included in this study were based on recommendations provided in the 
review article by Schmidt, et al. (2011), which identified key biomarkers for understanding 
depression physiology.4  In chapter 4, we analyzed pre-existing laboratory results.  In this 
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smaller and more recent VACS substudy, we were able to analyze a more expansive set of 
depression-specific biomarkers. 
Participant plasma (EDTA) and serum were collected during a clinical visit from 2005 – 
2006.  Laboratory analyses were conducted at the Laboratory for Clinical Biochemistry 
Research, University of Vermont.   
Growth Factor  Vascular endothelial growth factor (VEGF) concentration (pg/mL) was 
measured from participant serum using a sandwich ELISA (R&D Systems, Inc., USA). 
Inflammatory Markers  Chemiluminescent sandwich ELISA (R&D Systems, Inc., USA) was 
used to measure interleukin-6 (IL-6) concentration (pg/mL) in participant serum.  Plasma 
concentrations of tumor necrosis factor-α (TNF- α, pg/mL) were quantified using magnetic bead 
multiplex with flow-cytometry technique (Millipore Panel B).  High sensitivity C-reactive 
protein (hs-CRP) serum concentrations were measured with the Siemens BNIII Nephelometer. 
Endocrine Marker  Cortisol concentration (μg/dL), an endocrine marker, was analyzed with 
electrochemiluminescence immunoassay (Roche Elecys).  
Metabolic Markers  Serum leptin concentration (pg/mL) was measured using R&D Elisa. 
Fasting insulin concentration (μU/mL) was measured from participant serum with Roche Elecsys 
2010.  Metabolic marker concentrations glucose; HDL-c; LDL-c; and triglycerides were obtained 
from VA outpatient laboratory reports. 
Metabolic syndrome was defined using the World Health Organization definition.  The 
criteria requires (i) fasting glucose > 110 mg/dL OR diabetes / medication for diabetes OR 
insulin resistance; and two of the following: (ii) triglycerides ≥ 150 mg/dL and / or HDL-c < 35 
mg/dL; (iii) BMI > 30 kg/m2; (iv) SBP ≥ 140 mmHg and / or DBP ≥ 90 mm; or (v) 
microalbuminuria (urine albumin ≥ 20 g/min OR albumin:creatinine ratio ≥ 30 mg/g.  
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Medication for diabetes, insulin resistance, and measures of microalbuminuria were not available 
for this analysis.  Figure 5-1 illustrates the timeline of independent and dependent variables. 
Covariates 
Age, sex, and race/ethnicity were acquired through administrative data.  Medical data 
regarding hypertension, diabetes, serum lipids, renal function, anemia, hepatitis C virus (HCV) 
infection, and alcohol and cocaine abuse or dependence were obtained from baseline outpatient 
records, survey question instruments, and laboratory reports.  The VA additionally collected 
health factor data including body mass index (BMI; kg/m2). 
Statistical Analysis 
Chi-square analyses were used to compare the frequency of depressive symptom 
categories by HIV status.  Chi-square analyses and ANOVA were used to compare categorical 
and continuous baseline characteristics across the four HIV / depression groups as appropriate.   
In order to compare crude biomarker concentrations by HIV and depression status, we 
reported means with standard deviations for normally distributed biomarkers (cortisol, HDL-c, 
and LDL-c) and medians with interquartile ranges for biomarkers that were not normally 
distributed (VEGF, IL-6, TNF-α, hs-CRP, insulin, glucose, leptin, and triglycerides). 
Appropriate statistical tests were used to compare mean and median concentrations by 
depression and across the four HIV / depression groups.  For each group, we also reported the 
proportion of participants with biomarker concentrations in the highest quartile, except for the 
growth factor, VEGF, where we reported proportions in the lowest quartile.  Appropriate 
statistical tests were used to compare these proportions across groups. 
Standard multiple regression models were produced to model the association between 
depressive symptoms and biomarkers on a continuous scale.  Biomarkers that were not normally 
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distributed were log-transformed.  The first model was adjusted for age and race/ethnicity, and a 
second model added BMI.  We explored these models in the entire cohort and by HIV status. 
5.4 RESULTS 
The final sample included 303 veterans (195 HIV+, 108 HIV-).  Symptoms of major depression 
were common in this sample with 20.8% of the sample having PHQ-9 scores ≥ 10.  Mean PHQ-9 
scores did not differ significantly between HIV+ and HIV- participants (mean (SD), 4.73 (5.74) 
and 5.16 (6.13), respectively) and neither did depression symptom severity (Table 5-1). Age and 
BMI varied across the HIV/depression groups (Table 5-2).  In both HIV- and HIV+ participants, 
those with depression tended to be younger and have higher BMI.   
In those without HIV infection, median VEGF concentration did not differ significantly 
by depression status, but revealed a trend of being lower with symptoms of major depression 
(Table 5-3).  Similarly in those with HIV infection, the median concentration of VEGF was 
lower in those with depression compared to those without depression and those findings were 
statistically significant.  Concentrations of the three markers of inflammation (IL-6, TNF-α, and 
hs-CRP) and the endocrine marker (cortisol) were not significantly different by depression status 
in either HIV group.  Insulin, glucose, HDL-c, and LDL-c concentrations were not significantly 
different by depression status in the HIV+ and HIV- participants.  Leptin concentration was 
higher with depression in the HIV+ participants but not significantly different by depression 
status in the HIV- participants.  Conversely, triglyceride concentration was higher with 
depression in the HIV- participants but not significantly different by depression status in the 
HIV+ participants. 
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Table 5-4 provides the findings from liner regression models stratified by HIV status.  In 
adjusted models, depression was not associated with VEGF, IL-6, TNF-α, hs-CRP, cortisol, 
insulin, or HDL-c in participants with and without HIV infection.  In participants without HIV 
infection, depression was associated with increased concentrations of glucose and triglycerides 
and decreased concentrations of LDL-c, after adjusting for age, race/ethnicity, and BMI.  In 
HIV+ participants, depression was associated with increased concentrations of leptin when 
adjusting for age and race/ethnicity, but the association was no longer significant after including 
BMI in the model.  In models adjusted by age and BMI and stratified by race, depression was 
associated with decreased concentrations of VEGF in black participants but not in white 
participants (data not shown). 
We explored the association between depression and metabolic syndrome by HIV status. 
In the HIV- participants, the proportion of those with metabolic syndrome was significantly 
greater in those with symptoms of major depression (25.0% vs. 2.4%, respectively; p = 0.0014). 
In the HIV+ participants, PHQ-9 scores ≥ 10 were not associated with a significant difference in 
the proportion of those with metabolic syndrome compared to those with PHQ-9 scores < 10 
(15.4% vs. 11.5%, respectively; p = 0.59).  In an unadjusted logistic regression model, PHQ-9 
scores ≥ 10 were associated with metabolic syndrome (Table 5-5).  The association remained 
significant when the model was adjusted for HIV, but the association was no longer significant 
when the model was further adjusted for age and race/ethnicity. 
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5.5 DISCUSSION 
We provide a biomarker profile by depressive symptom severity in HIV+ and HIV- veterans.  
Depressive symptoms were associated with metabolic marker concentrations, but these trends 
differed between HIV+ and HIV- participants.  The association between the growth factor VEGF 
and depressive symptoms also varied by HIV status.  We did not find significant associations 
between depressive symptoms and concentrations of markers of inflammation or altered 
endocrine function in either HIV+ or HIV- participants in this cohort. 
VEGF, a molecule that promotes angiogenesis through vascular endothelial cell growth, 
is also associated with vasodilatation, transient tachycardia, hypotension, and decreased cardiac 
output in animal models.90, 91  Recent studies with depression describe mixed findings for VEGF 
levels.  Isung et al, reported that both VEGF from cerebral spinal fluid and plasma was 
associated with both depressive symptoms and suicidal ideation.92, 93  In a different study, MDD 
patients had higher expression of VEGF mRNA in peripheral leukocytes compared to those 
without MDD.94  We found that median concentrations of VEGF tended to be lower with 
symptoms of depression, but concentrations were only significantly different in those with HIV 
infection and the association was lost in models adjusted for age and race/ethnicity.  
Large bodies of evidence describe higher concentrations of inflammatory biomarkers 
among those with either HIV infection or depressive symptoms.  In studies comparing HIV+ 
adults to HIV- adults, hsCRP and IL-6 were higher among those with HIV infection.95-97 
Similarly, depressive symptoms were associated with higher concentrations of TNF-α, IL-6, and 
IL-1β.4  Higher concentrations of IL-6 were associated with vascular dysfunction and mortality 
in a cohorts of HIV+ adults.98, 99  In this sample, symptoms of major depression were not 
associated with significant differences in the median concentrations of IL-6, TNF-α, or hs-CRP, 
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and the adjusted models did not reveal significant associations between depressive symptoms 
and these markers of inflammation in either HIV group.  Our findings are similar, however, to a 
previous study that found no significant association between depressive symptoms and elevated 
levels of IL-6 in HIV+ participants.85  The endocrine marker, cortisol, was not associated with 
depressive symptoms in this cohort, though we expected a positive association.   
The metabolic markers provided the most significant differences with depressive 
symptoms, and the differences varied by HIV status.  In the HIV- participants, there were no 
significant differences in the concentrations of insulin, glucose, leptin, HDL-c, or LDL-c by 
symptoms of major depression. Triglyceride concentrations were significantly higher in the HIV- 
participants with PHQ-9 scores ≥ 10 compared to those without symptoms of depression.  In 
adjusted models within the HIV- group, symptoms of major depression were associated with 
increased concentrations of glucose and triglycerides and decreased concentrations of LDL-c. 
Crude concentrations of leptin were significantly higher with depressive symptoms in the HIV+ 
participants, but insulin, glucose, HDL-c, and LDL-c were not significantly different with PHQ-9 
scores ≥ 10.  In the model adjusted for age and race/ethnicity, symptoms of major depression 
were associated with higher concentrations of leptin, but the association was no longer 
significant after adding BMI to the model. 
Limitations of this study must be addressed.  Since this sample was selected from 
veterans, majority of the participants were men, so findings may not be generalizable to women.  
Second, the cross-sectional design of this study does not allow us to determine directionality or 
causality.  Prospective studies are required to understand how depressive symptoms and HIV 
infection influence biomarker concentration changes over time and whether these changes will 
lead to future cardiovascular disease events.  Third, we found in the previous study (Chapter 4 of 
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this dissertation), that the PHQ-9 score may have misclassification.  This definition of depression 
captures symptoms from the two weeks prior to completing the questionnaire.  Scores greater 
than ten may be due to (i) a transient one time episode of major depression symptoms, (ii) a 
chronic state of untreated depression, or (iii) or depression that is resistant to antidepressant 
therapy.  On the other hand, scores less than ten may be due to (i) depression that has been 
effectively managed through therapy or (ii) simply having to rare symptoms of depression.  
Repeated measures of depression symptom severity and biomarker concentrations would help us 
understand how these variables are associated.  Fourth, and perhaps most importantly, the sample 
size was small.  The trends in Table 5-3 were quite similar to the trends found in our previous 
study (Chapter 4, Table 4-5).  The findings may not be statistically significant due to inadequate 
power. 
Despite these limitations, our findings provide novel information.  This Three Site CVD 
Substudy allowed us to explore numerous biomarkers in HIV+ and HIV- veterans.  It is the first 
study to describe the biomarker profile of participants with depressive symptoms and HIV 
infection.  Depression in HIV- veterans is physiologically different from depression in HIV+ 
veterans.  The primary mechanisms driving the association between depressive symptoms and 
cardiovascular disease may differ between individuals with and without HIV infection. 
Findings from this study may direct future investigators in conducting mediation analyses 
to determine physiological mechanisms between depression and CVD in HIV- and HIV+ adults. 
In order to decrease the risk of CVD from depression, clinicians may need to take different 
approaches for treating HIV- and HIV+ patients. 
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5.6 TABLES AND FIGURES 
Table 5-1  Depression symptom severity among the total sample and HIV- and HIV+ 
participants 
PHQ-9 Scores Depression Categorization Total Sample 
(N = 303) 
HIV- 
(N = 108) 
HIV+ 
(N = 195) 
P value 
< 10, n (%) No major depression 240 (79.2) 84 (77.8) 156 (80.0) 0.6480 
10 – 14, n (%) Mild major depression 32 (10.6) 11 (10.2) 21 (10.8) 0.8741 
15 – 19, n (%) Moderate major depression 24 (7.9) 10 (9.3) 14 (7.2) 0.5209 
≥ 20, n (%) Severe major depression  7 (2.3) 3 (2.8) 4 (2.1) 0.6868 
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Table 5-2  Baseline participant characteristics by HIV status and symptoms of major depression 
(PHQ-9 ≥ 10) (N = 303) 
HIV-uninfected HIV-infected 
PHQ-9 < 10 PHQ-9 ≥ 10 PHQ-9 < 10 PHQ-9 ≥ 10 P value 
Characteristic (n = 84) (n = 24) (n = 156) (n = 39) 
Age, years, mean (SD) 55.4 (7.1) 53.0 (7.3) 55.0 (7.4) 49.8 (7.2) 0.0004 
Male, % 100 95.8 99.4 100 0.1499 
African American, % 78.6 91.7 78.2 69.2 
0.4972 
     White, % 14.3 4.2 15.4 15.4 
     Hispanic, % 4.8 4.2 3.9 12.8 
     Other, % 2.4 0.0 2.6 2.6 
Body mass index (kg/m2), mean (SD) 28.3 (5.1) 29.6 (5.7) 26.3 (6.0) 30.1 (20.2) 0.0480 
Systolic blood pressure, mean (SD) 129.9 (12.4) 131.2 (13.0) 128.9 (12.6) 128.2 (10.5) 0.7341 
Diastolic blood pressure, mean (SD) 78.6 (9.4) 82.7 (7.6) 80.3 (9.0) 81.1 (6.1) 0.1580 
Diabetes mellitus, % 17.9 29.2 23.1 20.5 0.6329 
Statin, % 25.0 12.5 28.2 28.2 0.4228 
Creatinine, mean (SD) 1.04 (0.17) 1.06 (0.21) 1.07 (0.27) 1.04 (0.21) 0.7718 
eGFR (mL/min/1.73 m3), mean (SD) 89.9 (20.0) 91.8 (24.6) 89.7 (25.5) 90.8 (21.3) 0.9761 
Hemoglobin, mean (SD) 14.0 (1.2) 14.3 (1.5) 14.0 (1.5) 14.1 (1.3) 0.7753 
Current smoking, % 50.0 70.8 50.6 51.3 
0.5539      Never, % 22.6 12.5 26.3 20.5 
     Past, % 27.4 16.7 23.1 28.2 
Alcohol abuse, % 63.1 79.2 50.0 61.5 0.0230 
Cocaine abuse, %  54.8 70.8 46.8 51.3 0.1490 
HCV infection, % 42.9 58.3 55.8 51.3 0.2520 
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HIV-uninfected HIV-infected 
PHQ-9 < 10 PHQ-9 ≥ 10 PHQ-9 < 10 PHQ-9 ≥ 10 P value 
Characteristic (n = 84) (n = 24) (n = 156) (n = 39) 
Antiretroviral therapy use, % -- -- 95.5 97.4 0.5881 





CD4+ count (count/µL), mean (SD) -- -- 494.9 (268.3) 532.9 (234.3) 0.4191 
CD4 nadir value, mean (SD) -- -- 212.2 (169.1) 240.7 (120.1) 0.2292 
CD8 Lab Results, mean (SD) -- -- 893.3 (379.1) 1012.5 (596.9) 0.2408 
CD4:CD8 ratio, mean (SD) -- -- 0.68 (0.64) 0.64 (0.39) 0.5806 
Abbreviations:  eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus; HDL, high-
density lipoprotein; HIV, human immunodeficiency virus; LDL, low-density lipoprotein 
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Table 5-2 Continued
Table 5-3  Biomarker profiles by HIV status and symptoms of major depression (PHQ-9 ≥ 10) 









PHQ-9 < 10 
(n = 84) 
PHQ-9 ≥ 10 
(n = 24) 
PHQ-9 < 10 
 (n = 156) 
PHQ-9 ≥ 10 











N = 239 
Median (IQR) 
≤ 25th percentile 
N = 75 
42.1 (24.1, 64.8) 
29.3% 
N = 15 




N = 120 
37.3 (27.7, 63.4) 
21.7% 
N = 29 



























N = 240 
Median (IQR) 
> 75th percentile 
N = 74 
3.2 (2.0, 5.2) 
29.7% 
N = 15 




N = 121 
2.8 (1.8, 4.5) 
22.3 
N = 30 








N = 238 
Median (IQR) 
> 75th percentile 
N = 73 
3.0 (2.2, 4.2) 
23.3% 
N = 15 




N = 121 
3.2 (2.5, 4.4) 
28.1% 
N = 29 








N = 210 
Median (IQR) 
> 75th percentile 
N = 68 
1.7 (0.85, 3.9) 
25.0% 
N = 12 




N = 105 
2.1 (0.95, 3.7) 
22.9% 
N = 25 














r Cortisol  
(ug/dL) 
N = 237 
Mean (SD) 
> 75th percentile 
N = 75 
15.2 (5.7) 
28.0% 





N = 117 
16.2 (6.3) 
25.6% 



















N = 168 
Median (IQR) 
> 75th percentile 
N = 45 
11.6 (6.7, 16.0) 
24.4% 
N = 12 




N = 91 
9.9 (5.5, 14.7) 
22.0% 
N = 20 








N = 301 
Median (IQR) 
> 75th percentile 
N = 82 
102.0 (90.0, 112.0) 
22.0% 
N = 24 




N = 156 
100.0 (90.0, 118.5) 
27.6% 
N = 39 








N = 211 
Median 
(IQR) 
> 75th percentile 
























N = 301 
Mean (SD) 
> 75th percentile 
N = 82 
48.3 (18.6) 
26.8% 





N = 156 
43.5 (14.5) 
21.8% 
















PHQ-9 < 10 
(n = 84) 
PHQ-9 ≥ 10 
(n = 24) 
PHQ-9 < 10 
 (n = 156) 
PHQ-9 ≥ 10 
 (n = 39) 
LDL-c 
(mg/dL) 
N = 301 
Mean (SD) 
> 75th percentile 
N = 82 
105.4 (29.9) 
26.8% 





N = 156 
97.6 (28.0) 
24.4% 











> 75th percentile 
N = 82 
92.0 (70.0, 144.0) 
13.4% 





N = 156 
119.1 (91.5, 206.0) 
28.9% 
N = 39 






Abbreviations:  HDL-c, high-density lipoprotein cholesterol; HIV, human immunodeficiency 
virus; IL-6, interleukin-6; LDL-c, low-density lipoprotein cholesterol; MDD, major depressive 
disorder; sCD14, soluble CD14. 
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Table 5-3 Continued
 Table 5-4  Association between symptoms of major depression (PHQ-9 ≥ 10) biomarkers, β 
(95% CI) 
VEGF IL-6 TNF-α 
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Model 1: age and race/ethnicity;  
Model 2: age, race/ethnicity, and BMI 
*P < 0.05; † P < 0.10
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Glucose Leptin HDL-c 



































































Model 1: age and race/ethnicity;  
Model 2: age, race/ethnicity, and BMI 
*P < 0.05; † P < 0.10
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Table 5-4 Continued
Table 5-5  Logistic regression models between symptoms of major depression and metabolic 
syndrome 
Model 1 Model 2 Model 3 
Characteristic OR 95% CI OR 95% CI OR 95% CI 
PHQ-9 ≥ 10 vs. < 10 2.59 (1.19, 5.63) 2.65 (1.21, 5.81) 2.73 (0.82, 4.90) 
HIV+ vs. HIV- -- -- 1.82 (0.78, 4.25) 1.88 (0.82, 5.50) 
Age (per 10 years) -- -- -- -- 1.00 (0.94, 1.05) 
White -- -- -- -- 1.00 [Reference] 
 African American -- -- -- -- 2.60 (0.59, 11.5) 
 Hispanic -- -- -- -- 2.36 (0.29, 19.3) 
 Other -- -- -- -- 8.89 (0.97, 81.5) 
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Figure 5-1.  Timeline of independent and dependent variables 
100 
6.0  DISSERTATION DISCUSSION 
6.1 MAJOR FINDINGS 
This dissertation provides new and important information about cardiovascular disease (CVD) 
outcomes and physiology of adults with co-occurring depression and HIV infection.  First, using 
data from over 80,000 veterans enrolled in the Veterans Aging Cohort Study, we found that HIV 
infection and major depressive disorder (MDD) are each associated with an increased risk of 
incident HF.  Participants with co-occurring HIV infection and MDD had the highest rates and 
risk of incident heart failure compared to participants with only one these conditions or neither 
condition.  These findings were robust.  In an analysis restricted to HIV+ participants, MDD was 
associated with incident heart failure, even after adjusting for HIV severity.  As an exploratory 
analysis we found that among those with MDD, baseline antidepressant use was associated with 
lower risk of incident HF events.  This study is the first to suggest MDD is an independent risk 
factor for HF in HIV+ adults. 
Understanding that depression and HIV pathophysiology overlap, we explored biomarker 
concentrations in two cohorts.  In a sample of 2,099 participants, MDD was associated with 
glucose concentrations in the highest quartile and PHQ-9 scores ≥ 10 were associated with 
higher triglyceride concentrations.  In models restricted by HIV status and adjusted for age, sex, 
and race/ethnicity, MDD was associated with increased concentrations of IL-6 and sCD14 in the 
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HIV- participants and associated with increased concentrations of glucose and decreased 
concentrations of HDL-c in the HIV+ participants.  In a smaller sample of 309 veterans, 
depression was associated with glucose, LDL-c, and triglyceride concentrations in HIV- 
participants, and leptin in HIV+ participants.  We hypothesized that co-occurring HIV infection 
and depression would result in excessive inflammation, coagulation, monocyte activation, and 
endocrine response, altered metabolism, and depleted growth factor.  In both of these samples, 
we found that depression was associated with altered concentrations of biomarkers, and that the 
changes observed in the HIV- participants were different from the changes observed in the HIV+ 
participants; but our findings did not support our hypotheses.  These findings indicate that the 
physiological pathways mediating depression and cardiovascular disease may differ with co-
occurring HIV infection.   
6.2 PUBLIC HEALTH SIGNIFICANCE 
Our health depends on the exposures we face across the lifecourse and how well our bodies adapt 
to these exposures.  Public health investigators aim to (i) discover the specific exposures that 
impact our health in positive and negative ways; (ii) determine which traits are associated with 
being healthy or ill; and (iii) provide evidence-based solutions for achieving a healthy state. 
Understandably, the field of public health is vast and requires experts that range from geneticists 
to environmental epidemiologists.  As it is impossible to become an expert in all things, we as 
public health investigators often specialize in a specific organ system or pathogen (e.g. traumatic 
brain injury or influenza).   We must remember to seek literature outside our field of expertise 
and consider how discoveries from other disciplines may impact our own findings.  This 
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dissertation illustrates the significance of asking cross-cutting, multi-disciplinary public health 
questions.   
The idea for this dissertation stemmed from my interest in infectious diseases.  As I 
explored the HIV literature, I discovered studies that provided hypotheses for the significant 
association between HIV infection and increased risk of cardiovascular disease.  During a 
seminar lecture, I learned about a second non-traditional risk factor for cardiovascular disease, 
i.e. depression.  The hypotheses to describe the pathophysiological mechanisms between HIV 
and CVD and between depression and CVD seemed to overlap.  I developed specific aims that 
incorporated findings from these three disciplines. As a result, this dissertation provides evidence 
that a mental health condition (depression) is a significant predictor of short-term physiological 
changes (biomarkers) and chronic disease risk (heart failure) in individuals with an infectious 
disease (HIV). 
The findings from this cross-cutting dissertation have many clinical implications and 
provide numerous new avenues for further investigation. Now that we know that depressive 
symptoms contribute to the burden of CVD among individuals with HIV, we must advocate for 
comprehensive healthcare.  HIV+ patients should be systematically screened for affective 
disorders.  To address symptoms of depression and their implications with cardiovascular 
disease, clinicians may need to consider different interventions depending on the HIV status of 
their patients. 
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6.3 FUTURE DIRECTIONS 
This dissertation is hypothesis generating and provides many opportunities for future analysis.  
Using the knowledge gained in Chapter 3, we now understand that co-occurring HIV infection 
and MDD leads to increased risk of heart failure (HF).  To further understand the etiology 
associated with this heart failure risk, we could analyze ejection fraction data and explain 
whether the HF is systolic or diastolic.  We could look at other CVD events, such as stroke or 
CVD mortality, and determine whether co-occurring HIV and depression also increases these 
risks.  Additionally, we could explore subclinical changes that occur before a CVD event.  For 
example, we could look at structural changes, such as intima-media thickness or coronary artery 
calcification, and functional changes, such as endothelial function or stress test performance. 
We used two definitions for depression, which classified participants as “depressed” or 
“not depressed” at a single time point.  To address the limitations related to this cross-sectional 
variable, we could study depression using repeated measures.  This prospective approach would 
help us understand how biomarker concentrations and CVD risk are impacted by transient 
episodes and chronic states of depression. It would also be important to further understand how 
antidepressant use affects depressive symptoms, biomarker concentrations, and long-term 
outcomes.  A randomized controlled trial would help us understand whether effective 
management of depression reduces CVD risk in HIV+ and HIV- participants. 
Finally, depression and HIV infection are just single examples of an affective disorder 
and a chronic inflammatory condition.  We could explore CVD risk with any combination of 
mental health conditions and inflammatory conditions, with their respective therapies.  Examples 
include anxiety and systemic lupus erythematosus or post-traumatic stress disorder and 
rheumatoid arthritis.  Epidemiologists have many options with these multi-disciplinary studies. 
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APPENDIX A: LITERATURE REVIEW SUMMARY TABLES: HEART FAILURE 
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Association Key findings 
Whooley 
(1998)47 7518 GDS-SF ≥ 6 
Congestive HF 
mortality based on 
adjudicated hospital 





72 0.00 100 Elderly 
HR = 3.2 
(1.3 - 8.0) 
Depressive 
symptoms associated 




(1999)14 1749 CES-D ≥ 16 






77.8 41.1 79.5 
Elderly of 
Connecticut 
RR = 1.10 
(p = 0.65) 
Depression was not 
independently 
associated w/ 
incidence of HF 
Abramson 
(2001)11 4538 
CES-D ≥ 16 at 
baseline 












HR = 2.59 
(1.57 - 4.27) 
Depression was a 
significant risk of HF 




CES-D ≥ 21 at 
baseline 
Incident HF based 




14 years Mean 74 41.9 
Pre-
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♀ HR = 1.96 
(1.11 - 3.26) 
♂ HR = 0.62 
(0.23 - 1.71) 
Depression was a 
significant risk in 
women, but not in 








depression defined as 
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on self-report of 
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medications, or 
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of Non-ischemic CVD 
even after adjusting 
for age and sex 
Vaccarino 
(2007)13 559 
BDI < 10 & no history 
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BDI ≥ 10 OR history 
of depression 
BDI ≥ 10 AND history 
of depression 
Exploratory analysis 
conducted on HF 
due to few events 













CRP (p < 
0.0001) and IL-6 
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found significant risk 
of HF (HR not 
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IL-6 and CRP 
explained only some 
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Major Depressive 
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Structured Clinical 
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CES-D ≥ 8 at
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Fibrosis markers: 
Procollagen type I 
(PIP); Type I 
collagen (CITP); & 




















Procollagen type I 
even after adjustment 




No depression: 0 ≤ 
BDI < 10 
Mild depression: 10 ≤ 
BDI < 20 
Moderate - severe 
depression: BDI ≥ 20 
Subclinical LV 
changes based on 
echocardiography 












Higher LV mass 
index (p = 0.019) 
and lower TDI Ea 







subclinical changes to 






codes in VHA records 
Incident HF; ICD-9-
CM in VHA records Prospective
Mean 
62.8 93.4 78.7 
VA patients; 
free of CVD; 
age 50 – 80 
Adjusting for 
CVD risk factors 
& substance 
abuse 
HR = 1.11  
(1.04-1.18) 
MDD, anxiety, and 
MDD/anxiety were 
each associated with 






Hospital Anxiety & 
Depression Scale 
(HADS) 
Incident HF; linkage 
w/ medical records 
or by the National 
Cause of Death 
Registry 

















increased risk of HF 
in a dose-response 









Patients feeling down/ 
depressed/ hopeless 
divided into 2 
categories: symptoms 
more than half the 
days of the week & 
those with less 
frequent symptoms 




OR = 2.54 
(1.61-4.01) 
Those who reported 
being depressed 
more than half of the 
days of the week had 
higher odds of CHF 
compared to those 
who reported being 
depressed less often 
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Table 6-1 Continued
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HIV+ compared to HIV-: 
 LV diastolic diameter 
 LV systolic diameter 
 LV fractional shortening 
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 isovolumetric relaxation 
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 Peak systolic velocity 
tissue 
















wall peak systolic 
circumferential 
strain (Ecc) & 
early diastolic 
strain rate (SRE) 





40 60.9 0 
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(%) White (%) 
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inclusions Measure of Association Key findings 
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(2011)25 8486 
1 or more 
inpatient 






1 or more inpatient 
and/or 2 or more 
outpatient ICD-9 
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(1.39 - 2.36) 









level ≥ 500 
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but not when 
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HIV+ normotenstives: 42.8 
g  
HIV- hypertensives: 44.5 g 
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Afr Am w/ HIV/AIDS: 34% 
Afr Am, uninfected: 28% 
White w/ HIV/AIDS: 25% 















whites w/ HIV 
Womack 
(2015) 2187 HIV 
1 inpatient / 2 or 
more outpatient 





0 Approx 30 
VACS; women 
free of CVD 





risk of HF in 
women 
Abbreviations: AIDS, acquired immune deficiency syndrome; HF, heart failure; HIV, human immunodeficiency virus; HR, hazard 
ratio; ICD-9-CM, The International Classification of Diseases, 9th Revision, Clinical Modification; LHS, Large Health Study of 
Veteran Enrollees; LV, left ventricle; MRI, magnetic resonance imaging; NHDS, United States National Hospital Discharge Surveys; 
SCOPE, Study of the Consequences of the Protease Inhibitor Era; VACS-VC, Veterans Aging Cohort Study – Virtual Cohort
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Table 6-3 Summary of Literature: Depression, HIV, biomarkers, and cardiovascular disease 
Study participants 
Author 
(year) N Age (years) 
Important 
inclusions Exposure Outcome Key findings 
VEGF – Vascular endothelial growth factor – is a protein that stimulates angiogenesis.  Peripheral VEGF is measured from plasma collected in EDTA.  
Reference range: 31 – 86 pg/mL 104 
Ventriglia et al 
(2009)105 25 Drug-free pts 
Depressed in- and
outpts & controls Serum VEGF No significant differences 
Kahl et al 




Serum VEGF Elevated VEGF in depressed pts 
Lee & Kim (2012)107 35 Drug-free pts 
Moderate 
depression & acute 
episodes of 
depression 
Plasma VEGF Increased plasma VEGF levels in depressed 
Clark-Raymond et al 
(2014)108 
MDD subjects 
prior to treatment 
vs. healthy 
controls 
Plasma VEGF VEGF higher with MDD 





10) vs. healthy, no
affective disorders 
Serum VEGF Increased serum VEGF levels in the depressive subjects vs. controls 
Taimeh et al 
(2013)87 Review article VEGF HF Reduced VEGF in models of advanced HF 
Kaidaniuk et al 
(2011)110 Review article VEGF CVD 
Angiogenesis plays a protective role in 
ischemic heart disease & MI 
Extends life for pts after stroke 
IL-6 – Interleukin-6 – is a cytokine with pro-inflammatory and anti-inflammatory effects.  IL-6 is measured in serum and helps to identify inflammatory 
conditions.  Reference range: < 17.4 pg/mL104, 111 
Howren et al 
(2009)76 
62 
studies N/A Meta-analysis 
Depressive
symptoms IL-6 
Circulating peripheral IL-6 was significantly 




(year) N Age (years) 
Important 
inclusions Exposure Outcome Key findings 









in pts w/ major 
depression 
Major depression 
(DSM criteria) IL-6 
IL-6 concentrations were significantly higher in 
depressed subjects compared to controls  
(p < .00001) 
Fumaz et al 















Strong correlation between IL-6 & 
psychological stress (r = .81) 
Anxiety / depression were associated with 
higher levels of IL-6; association not 
significant in models adjusted by age 



















(hospital stays for 
nonfatal MI, stroke, 
congestive heart failure, 
and CVD-related death) 
Possible mediators: 
CRP & IL-6 
Depression associated with 25% higher IL-6 
(p = 0.04) 
Possible depression associated with 28% 
higher IL-6 (p = 0.01) 
Depression was a significant predictor of CVD 
(HR 2.58, p = 0.0009) 
Possible depression was not a significant 
predictor of CVD (HR 1.12, p = 0.68) 
Addition of IL-6 decreased estimate for 
depression by 4% 
Inflammatory biomarkers explain only a small 
proportion of the association between 
depression and CVD incidence 





45 – 77 
& 







IL-6 levels were 152% higher (p < .001) 
among HIV-infected participants compared 
with levels in MESA study participants 
IL-6 levels were 62% (p < .001) higher among 






(year) N Age (years) 
Important 
inclusions Exposure Outcome Key findings 









HIV IL-6  (>75th percentile) 
HIV+ veterans with HIV-RNA ≥ 500 copies/mL 
had a significantly higher prevalence of 
elevated IL-6; OR = 1.54; 95% CI, 1.14 – 
2.09) 
HIV+ veterans with CD4 count <200 cells/µL 
had a significantly higher prevalence of 
elevated IL-6; OR = 2.25; 95% CI, 1.60 – 
3.16) 
Orus et al 
(2000) 112 87 
Mean: 
57 CHF patients 
Cytokines 
Il-6, IL-1β, TNF-α, 
IL-2-sR 
Death, new HF 
episodes, & need for 
heart transplantation 
Increased IL-6 was a predictor of the 
combined outcome: death, new HF episodes, 
& need for heart transplantation 
Duprez et al 
(2012)113 5098 
Mean: between
49.8 – 56.3 
HIV patients 
enrolled in the 
SMART study 
IL-6 
CVD (CVD death, non-
fatal MI, non-fatal stroke, 
congestive HF, coronary 
revascularization, CAD 
requiring drug treatment, 
and peripheral artery 
disease) 
Adjusted HR for CVD Q4 vs Q1: 4.65 (2.61, 
8.29) 
TNF-α – Tumor Necrosis Factor - alpha – is an acute phase reactant that is detectable during systemic inflammation.  TNF-α is measured in serum. 
Reference range: < 5.6 pg/mL104 









in pts w/ major 
depression 
Major depression 
(DSM criteria) TNF-α 
TNF-α was increased in depressed subjects 













sTNFR1 & 2, IL-1ra, IL-
6, CRP 
Cognitive/affective depressive symptoms were 
associated with sTNFR1 & sTNFR2 
prospectively 
Somatic/affective depressive symptoms were 
associated with sTNFR2 prospectively 
Rauchhaus et al 
(2000)115 152 
Mean: 
61 CHF patients 
TNF-α, sTNFR1 & 
2, IL-6, sCD14 
Mortality  
(mean follow-up time = 
34 months) 
sTNF-R1 was the strongest predictor of 





(year) N Age (years) 
Important 
inclusions Exposure Outcome Key findings 
Deswal et al 
(2001) 116 1200 
Mean: 
between 







sTNFR1 & 2, sIL-
6 R 
Mortality Increased levels of TNF, IL-6, sTNFR1 & 2 were associated with increased mortality 
hs-CRP – high-sensitivity C-reactive protein – is an acute phase reactant that is detectable during systemic inflammation.  Hs-CRP is measured in serum 
and is helpful in assessing  cardiovascular disease risk.   
Reference ranges: Low risk: < 1.0 mg/L; Average risk: 1.0 – 3.0 mg/L; High risk: > 3.0 mg/L; Acute inflammation: > 10.0 mg/L104, 111 






Circulating peripheral CRP was significantly 
associated with diagnosis of major depression 



















(hospital stays for 
nonfatal MI, stroke, 
congestive heart failure, 
and CVD-related death) 
Possible mediators: 
CRP & IL-6 
Depression associated with70% higher CRP 
(p = 0.0008) 
Possible depression associated with 30% 
higher CRP (p = 0.02) 
Depression was a significant predictor of CVD 
(HR 2.58, p = 0.0009) 
Possible depression was not a significant 
predictor of CVD (HR 1.12, p = 0.68) 
Addition of CRP decreased estimate for 
depression by 13% 
Inflammatory biomarkers explain only a small 
proportion of the association between 
depression and CVD incidence 





45 – 77 
& 







hsCRP levels were 50% higher (p < .001) 
among HIV-infected participants compared 
with levels in MESA study participants 
hsCRP levels were 55% (p < .001) higher 






(year) N Age (years) 
Important 
inclusions Exposure Outcome Key findings 




49.8 – 56.3 
HIV patients 
enrolled in the 
SMART study 
Hs-CRP 
CVD (CVD death, non-
fatal MI, non-fatal stroke, 
congestive HF, coronary 
revascularization, CAD 
requiring drug treatment, 
and peripheral artery 
disease) 
Adjusted HR for CVD Q4 vs Q1: 2.10 (1.40, 
3.16) 
D-dimer is a marker of coagulation.  In a normal state, D-dimer is undetectable.  It is elevated in peripheral blood as a result of blood formation and 
fibrinolysis (blood clot degradation).  D-dimer is measured in plasma collected in sodium citrate.  The reference range is ≤ 0.5 mcg/mL Fibrinogen 
Equivalent Units 104, 111 
Von Kanel et al 














Depressive symptoms were associated with 
stress-induced changes in D-dimer levels over 
time (p = .011) 
With depressive symptoms, there was an 
attenuated immediate d-dimer stress response 
and delayed recovery of d-dimer levels post-
stress (prolonged hypercoagulability) 
Neuhaus et al 
(2010)95 5880 45 – 77 
SMART study 
/ MESA HIV d-dimer 
d-dimer levels were 94% higher (p < .001) 
among HIV-infected participants compared 
with levels in MESA study participants 




51.8 – 53.5 




HIV D-dimer  (>75th percentile) 
HIV+ veterans with HIV-RNA ≥ 500 copies/mL 
had a significantly higher prevalence of 
elevated d-dimer; OR = 1.97; 95% CI, 1.44 – 
2.71) 
HIV+ veterans with CD4 count <200 cells/µL 
had a significantly higher prevalence of 
elevated d-dimer; OR = 1.68; 95% CI, 1.22 – 
2.32) 




49.8 – 56.3 
HIV patients 
enrolled in the 
SMART study 
D-dimer 
CVD (CVD death, non-fatal 
MI, non-fatal stroke, 
congestive HF, coronary 
revascularization, CAD 
requiring drug treatment, 
and peripheral artery 
disease) 






(year) N Age (years) 
Important 
inclusions Exposure Outcome Key findings 
Neuhaus et al 
(2010)95 5880 45 – 77 
SMART study 
/ MESA HIV Cystatin C 
Cystatin C levels were 27% higher (p < .001) 
among HIV-infected participants compared 
with levels in MESA study participants 
sCD14 is a marker of monocyte activation.  It is a biomarker that can be used to monitor monocyte resonse to lipopolysaccharide (LPS), intestinal 
permeability, and microbial translocation 104, 111 












activation of monocytes 
Monocytes released the same amounts of 
prostaglandin E2 (PGE2) 
Monocytes from depressed patients were 
dramatically less reactive to 
lipopolysaccharide 









The levels of sCD14 did not differ between the 
depressed patients and the healthy controls at 
any time 




51.8 – 53.5 




HIV sCD14  (>75th percentile) 
HIV+ veterans with CD4 count <200 cells/µL 
had a significantly higher prevalence of 
elevated sCD14; OR = 2.60; 95% CI, 1.64 – 
4.14) 




45 - 50 
SMART study 
participants 




Subjects with the highest quartile of sCD14 
levels had a 6-fold higher risk of death than 
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